US20230389945A1 - Microprojection arrays with microprojections having large surface area profiles - Google Patents
Microprojection arrays with microprojections having large surface area profiles Download PDFInfo
- Publication number
- US20230389945A1 US20230389945A1 US18/303,333 US202318303333A US2023389945A1 US 20230389945 A1 US20230389945 A1 US 20230389945A1 US 202318303333 A US202318303333 A US 202318303333A US 2023389945 A1 US2023389945 A1 US 2023389945A1
- Authority
- US
- United States
- Prior art keywords
- microprojections
- microprojection
- skin
- degrees
- arrays
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003491 array Methods 0.000 title description 91
- 239000000758 substrate Substances 0.000 claims abstract description 18
- 230000007704 transition Effects 0.000 claims abstract description 11
- 239000007787 solid Substances 0.000 claims description 12
- 210000003491 skin Anatomy 0.000 description 104
- 229960005486 vaccine Drugs 0.000 description 43
- 238000000576 coating method Methods 0.000 description 30
- 230000035515 penetration Effects 0.000 description 29
- 239000011248 coating agent Substances 0.000 description 27
- 238000000034 method Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 230000030833 cell death Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 238000013461 design Methods 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 230000000149 penetrating effect Effects 0.000 description 8
- 230000009851 immunogenic response Effects 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000037368 penetrate the skin Effects 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000036572 transepidermal water loss Effects 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009118 appropriate response Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 1
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
- A61B17/205—Vaccinating by means of needles or other puncturing devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
Definitions
- the invention is generally directed to devices and methods for intradermal delivery of active agents into the skin, more particularly, the invention is directed to devices and methods for improving the immunogenicity of vaccine preparations by intradermal delivery of the vaccine via a microprojection array in which the geometry of the projections have been designed to improve skin penetration.
- the desired active agent can be applied either as a liquid formulation or as solid, powdered vaccine particles.
- the process of intradermal injection employs micron-sized needles that are inserted 1.5 mm perpendicularly into the skin, and which inject approximately 100-200 ⁇ l of a liquid vaccine formulation into the dermal skin layers.
- Microneedle arrays are made of coated solid microneedles or biodegradable microneedles. These are inserted into the dermal layers of the skin where either the coating is dissolved, or the microneedle itself dissolves in place.
- microprojection arrays In addition to questions surrounding the ideal immune targeting location in the skin, the level of cellular/tissue damage caused by microprojection arrays is also an issue. This damage may be a large contributing factor to the immune response and the appropriate level of damage is an issue that is being explored.
- the mechanism of delivery of microprojection arrays to the skin also affects the level of cellular/tissue damage caused by microprojection arrays.
- precise delivery of microprojection arrays to a targeted depth in the skin can be challenging.
- 7,497,980 describes the manufacture of moulds for microneedles arrays are triangular as well as pyramidal and include microneedles that are solid as well as those through which a channel courses or those with grooves carved therein.
- U.S. Pat. No. 7,591,806 describes microblades or microdevices that are used as biological delivery devices that will puncture the skin.
- U.S. Pat. No. 6,537,264 discloses blade-type microneedles that are used to sample bodily fluids.
- US Patent Publication No. 2007/0293815 discloses microprojection arrays for penetrating the skin and delivering a vaccine.
- microneedles that are formed from cutting metal with a laser and then bending the metal to form the microneedles.
- Prausnitz, M. R., Coated Microneedles for Transdermal Delivery, J. Controlled Release Soc. 117.2 (2007) 227-237 describe the use of sheet metal to fashion microneedles.
- US Patent Publication No. 2011/0021996 describes a microneedle array in which the microneedles have a conduit through which an active substance can be inserted into a body through the skin.
- microprojection arrays with appropriate microprojection geometry coupled with an understanding of the mechanical parameters of vaccine placement, skin puncture and mechanically induced cellular damage so that a more efficient system of delivering vaccine to the skin may be provided.
- the microprojection arrays of the present invention provide devices with greater vaccine loading and delivery than previous designs with more precise targeting within the skin.
- the present invention seeks to provide a microprojection array comprising a substrate with a plurality of microprojections protruding from the substrate wherein the microprojections have a tapering hexagonal shape and comprise a tip and a base wherein the base has two substantially parallel sides with a slight draught angle of approximately 1 to 20 degrees up to a transition point at which point the angle increases to from about 20 degrees to about 70 degrees.
- the substrate is at least one of:
- the microprojection array includes a number of microprojections arranged in a line.
- the line is at least one of:
- microprojections in a line typically have a common base.
- the microprojection array typically includes a number of spaced apart lines.
- the spacing of the microprojections between adjacent lines is at least one of:
- the spacing between successive microprojections is at least one of:
- each microprojection terminates in an elongate edge.
- the tip has a width of from about 1 ⁇ m to about 2 ⁇ m and a length of about 20 ⁇ m to about 2 mm
- the tip has a width of about 1 ⁇ m and a length of about 20 ⁇ m.
- the base has a length of from about 30 ⁇ m to about 2 mm.
- the base has a length of about 80 ⁇ m.
- the base is greater in length than the tip.
- the base has a thickness of about 5 ⁇ m to 50 ⁇ m.
- the base has a cross sectional length:thickness aspect ratio of about 2:1 to 5:1.
- At least one of the microprojections is coated with a vaccine antigen.
- the amount of the vaccine antigen is about 10 ng to about 10 ⁇ m.
- the amount of vaccine antigen is about 10% to about 50% less than the amount of vaccine antigen delivered by intramuscular administration.
- the administration of the vaccine antigen provides a greater immunogenic response when administered to a human than a comparable amount of vaccine antigen administered by intramuscular injection.
- the administration of the vaccine antigen provides a greater immunogenic response when administered to a human than a comparable amount of vaccine antigen administered with a microprojection array with conical or cylindrical microprojections.
- microprojections typically have an effective cross-sectional area which is unchanged by the addition of the coating.
- the present invention seeks to provide a method of administering a vaccine to a human comprising applying the microprojection array as described above to a human's skin.
- the microprojection array includes a number of microprojections arranged in a line, and wherein the method includes applying the microprojection array to a human's skin in a direction of movement including a component of movement aligned with the line.
- the line is a straight line and the method includes applying the microprojection array to the skin in a direction perpendicular to the skin and laterally parallel to the skin in the direction of the line.
- the line extends circumferentially around an axis and the method includes applying the microprojection array to the skin in a direction perpendicular to the skin whilst rotating the microprojection array around the axis.
- the present invention seeks to provide a microprojection array comprising a substrate with a plurality of microprojections protruding from the substrate wherein the microprojections have a tapering octagonal shape and comprise a tip and a base wherein the base has two substantially parallel sides with a slight draught angle of approximately 1 to 20 degrees up to a transition point at which point the angle increases to from about 20 degrees to about 70 degrees.
- the substrate is at least one of:
- the microprojection array includes a number of microprojections arranged in a line.
- the line is at least one of:
- microprojections in a line typically have a common base.
- the microprojection array typically includes a number of spaced apart lines.
- the spacing of the microprojections between adjacent lines is at least one of:
- the spacing between successive microprojections is at least one of:
- each microprojection terminates in an elongate edge.
- the tip has a width of from about 1 ⁇ m to about 2 ⁇ m and a length of about 20 ⁇ m to about 2 mm.
- FIG. 1 is an SEM image of one embodiment of uncoated microprojections of the present invention
- FIG. 2 is an image of skin stained to show live (green) and dead (magenta) cells following administration of one embodiment of microprojections of the present invention
- FIG. 3 is a plot of anti-Influenza antibody levels of sera from C57BL/6 mice determined by indirect ELISA plotted as 50% titers;
- FIG. 4 is a plot of day 21 IgG Titers for 5 ng, 50 ng and 500 ng influenza doses administered intramuscularly, intradermally and by microprojection array TP and NP;
- FIG. 5 A is a schematic plan view of an example of a microprojection array
- FIG. 5 B is a schematic front view of a line of microprojections of the microprojection array
- FIG. 6 A is a schematic front view of an example of a microprojection
- FIG. 6 B is a schematic side view of the microprojection.
- FIG. 6 C is a schematic plan view of the microprojection.
- the present invention relates to microprojection arrays where the microprojection design provides an alternative mode of skin puncture and vaccine delivery into the skin.
- the microprojections of the present invention are designed to have a large surface area to frontal profile design while maintaining a high density of microprojections on the array.
- the microprojection arrays of the present invention have a plurality of microprojections that are located upon a base.
- the microprojection have a shape that from a top down perspective is approximately an extended octagon.
- the microprojections have a shape that from a top down perspective is approximately an extended hexagon with two parallel sides being extended to give a rectangular profile with triangular ends ( FIG. 1 ).
- the microprojections may be aligned in parallel lines with spacing between the edges of the microprojections.
- the microprojections may extend vertically to a length that will provide for drugs or vaccines to be delivered to the desired location within the skin.
- the microprojections of the microprojection arrays of the present invention may be solid or non-porous or contain hollow portions therein. In some embodiments the microprojections are solid and non-porous and do not contain any hollow portion therein. In preferred embodiments the devices of the present invention do not contain reservoirs.
- the projections may be coated. Accordingly, one way of providing material for delivery to the biological subject is by providing the material within the coating.
- the coating may include a vaccine for providing an immunological response within the subject.
- the coating may be provided in liquid or non-liquid forms, and may further include ingredients other than the material to be delivered, such as an adjuvant. Suitable coating formulations for use with projections patches and methods of applying such coatings to the projections are known, as described, for example, in WO/2010/042996 and WO/2009/079712.
- non-liquid coating will be understood to include a coating that is applied in a liquid form and allowed to dry or otherwise solidify to thereby form a non-liquid coating.
- the non-liquid coating may act as an additional substantially solid layer of material which can be used to even further adjust the geometry of the projections by optionally causing the projections to have an effective profile of a different shape to the underlying uncoated profile of the projections as initially fabricated.
- the microprojections of the present invention are less sensitive to coating thickness as it relates to skin penetration.
- the thickness of the coating affects the cross-sectional area of the microprojection thereby affecting the ability of the microprojection to penetrate the skin at a given velocity.
- the effective cross-sectional area is little changed by the addition of the coating, thus the velocity required for skin penetration is relatively constant.
- the microprojection arrays have a substrate with a plurality of microprojections protruding from the substrate wherein the microprojections have a tapering hexagonal shape and comprise a tip and a base wherein the base has two substantially parallel sides with a slight draught angle of approximately 1 to 20 degrees up to a transition point at which point the angle increases to from about 20 degrees to about 70 degrees.
- the ends of the microprojections may be blunted to provide an extended octagonal profile.
- the profiles of the microprojections of the present invention may define extended hexagonal or octagonal shapes the edges of the profiles may be somewhat rounded depending on the method of manufacture of the microprojections and microprojection arrays.
- the draught angle may be between about 0 to 30 degrees or about 0 to 25 degrees or about 0 to 20 degrees or about 0 to 15 degrees or about 0 to 10 degrees, or about 1 to 30 degrees or about 1 to 25 degrees or about 1 to 20 degrees or about 1 to 15 degrees or about 1 to 10 degrees, or about 2 to 30 degrees or about 2 to 25 degrees or about 2 to 20 degrees or about 2 to 15 degrees or about 2 to 10 degrees, about 3 to 30 degrees or about 3 to 25 degrees or about 3 to 20 degrees or about 3 to 15 degrees or about 3 to 10 degrees, about 4 to 30 degrees or about 4 to 25 degrees or about 4 to 20 degrees or about 4 to 15 degrees or about 4 to 10 degrees, or about 5 to 30 degrees or about 5 to 25 degrees or about 5 to 20 degrees or about 5 to 15 degrees or about 5 to 10 degrees.
- the transition point angle may be between about 20 to 70 degrees or about 20 to 65 degrees or about 20 to 60 degrees or about 20 to 55 degrees or about 20 to 50 degrees, or about 20 to 45 degrees or about 20 to 40 degrees or about 20 to 35 degrees or about 20 to 30 degrees or about 20 to 25 degrees, about 25 to 70 degrees or about 25 to 65 degrees or about 25 to 60 degrees or about 25 to 55 degrees or about 25 to 50 degrees, about 25 to 45 degrees or about 25 to 45 degrees or about 25 to 40 degrees or about 25 to 35 degrees or about 25 to 30 degrees, or about 30 to 70 degrees or about 30 to 65 degrees or about 30 to 60 degrees or about 30 to 55 degrees or about 30 to 50 degrees or about 30 to about 45 degrees or about 30 to about 40 degrees or about 30 to about 35 degrees. In preferred embodiments the transition point angle will be greater than the draught angle.
- a sharp blade-like tip will allow for enhanced penetration of the microprojections into the skin while also generating an enhanced localized cell death/bystander interaction in the skin with a different profile than conical microprojection arrays.
- the sharp blade-like tips of the microprojections may also increase the level of danger signals and antigen to more live cells thereby increasing the physical adjuvant effect of microprojections and thereby improving immune responses.
- skin puncture is a function of crack formation in the skin and the subsequent expansion of these cracks. While high density microprojection arrays have each individual microprojection initiating a crack (which absorbs substantial energy), the microprojection arrays of the present invention provide a line of contact rather than a single point of contact.
- microprojections may enter the skin more easily allowing internal skin surface area contract with the penetrating surface. Significantly more surface area of the protrusion can enter the skin without a large increase in energy.
- the microprojection profile of the microprojection arrays of the present invention is wider and thinner than current conical or circular microprojection profiles.
- the microprojection arrays of the present invention reduce the number of penetrations made upon entry to the skin, increase the area of the microprojection in the skin and exploit surface crack propagation to enhance overall penetration and reduce the overall energy required to puncture the skin.
- the microprojection array may be delivered to the skin surface by an applicator.
- microprojection arrays may be delivered by direct vertical application onto skin or a lateral movement on skin which will allow the blades of the microprojections to cut the skin.
- the microprojection arrays of the present invention provide a higher level of cell death per projection than the standard conical microprojection and generate significantly improved immune responses compared to the standard conical microprojection. Therefore, the microprojections of the present invention provide an increased and controlled physical adjuvantation effect in the skin thereby significantly improving immunogenicity.
- the tip of the microprojections of the present invention may have a width of about 0.5 ⁇ m, or about 1.0 ⁇ m, or about 1.5 ⁇ m, or about 2.0 ⁇ m, or about 2.5 ⁇ m, or about 3.0 ⁇ m, or about 3.5 ⁇ m, or about 4.0 ⁇ m, or about 4.5 ⁇ m, or about 5.0 ⁇ m.
- the tip of the microprojections of the present invention may have a width of from about 0.5 ⁇ m to about 5.0 ⁇ m, or from about 0.5 ⁇ m to about 4.5 ⁇ m, or from about 0.5 ⁇ m to about 4.0 ⁇ m, or from about 0.5 ⁇ m to about 3.5 ⁇ m, or from about 0.5 ⁇ m to about 3.0 ⁇ m, or from about 0.5 ⁇ m to about 2.5 ⁇ m, or from about 0.5 ⁇ m to about 2.0 ⁇ m, or from about 0.5 ⁇ m to about 1.5 ⁇ m, or from about 0.5 ⁇ m to about 1.0 ⁇ m, or from about 1.0 ⁇ m to about 5.0 ⁇ m, or from about 1.0 ⁇ m to about 4.5 ⁇ m, or from about 1.0 ⁇ m to about 4.0 ⁇ m, or from about 1.0 ⁇ m to about 3.5 ⁇ m, or from about 1.0 ⁇ m to about 3.0 ⁇ m, or from about 1.0 ⁇ m to about 2.5 ⁇ m, or from
- the tip of the microprojections of the present invention may have a length of about 20 ⁇ m, or about 30 ⁇ m, or about 40 ⁇ m, or about 50 ⁇ m, or about 60 ⁇ m, or about 70 ⁇ m, or about 80 ⁇ m, or about 90 ⁇ m, or about 100 ⁇ m, or about 150 ⁇ m, or about 200 ⁇ m, or about 250 ⁇ m, or about 500 ⁇ m, or about 1000 ⁇ m, or about 1500 ⁇ m, or about 2000 ⁇ m.
- the tip of the microprojections of the present invention may have a length of from about 10 ⁇ m to about 2 mm, or from about 10 ⁇ m to about 1.5 mm, or from about 10 ⁇ m to about 1 mm, or from about 10 ⁇ m to about 900 ⁇ m, or from about 10 ⁇ m to about 800 ⁇ m, or from about 10 ⁇ m to about 700 ⁇ m, or from about 10 ⁇ m to about 600 ⁇ m, or from about 10 ⁇ m to about 500 ⁇ m, or from about 10 ⁇ m to about 400 ⁇ m, or from about 10 ⁇ m to about 300 ⁇ m, or from about 10 ⁇ m to about 200 ⁇ m, or from about 10 ⁇ m to about 100 ⁇ m, or from about 10 ⁇ m to about 90 ⁇ m, or from about 10 ⁇ m to about 80 ⁇ m, or from about 10 ⁇ m to about 70 ⁇ m, or from about 10 ⁇ m to about 60 ⁇ m, or from about 10 ⁇ m to about 70 ⁇ m, or from
- the base of the microprojections of the present invention may have a length of about 25 ⁇ m, or about 30 ⁇ m, or about 35 ⁇ m, or about 40 ⁇ m, or about 45 ⁇ m, or about 50 ⁇ m, or about 55 ⁇ m, or about 60 ⁇ m, or about 65 ⁇ m, or about 70 ⁇ m, or about 75 ⁇ m, or about 80 ⁇ m, or about 85 ⁇ m, or about 90 ⁇ m or about 100 ⁇ m or about 200 ⁇ m, or about 300 ⁇ m, or about 350 ⁇ m, or about 400 ⁇ m, or about 450 ⁇ m, or about 500 ⁇ m, or about 550 ⁇ m, or about 600 ⁇ m, or about 650 ⁇ m, or about 700 ⁇ m, or about 750 ⁇ m, or about 800 ⁇ m, or about 850 ⁇ m, or about 900 ⁇ m or about 1000 ⁇ m or about 1500 ⁇ m or about 2000 ⁇ m.
- the base of the microprojections of the present invention may have a length of from about 30 ⁇ m to about 2 mm, or from about 30 ⁇ m to about 1.5 mm, or from about 30 ⁇ m to about 1 mm, or from about 30 ⁇ m to about 900 ⁇ m, or from about 30 ⁇ m to about 800 ⁇ m, or from about 30 ⁇ m to about 700 ⁇ m, or from about 30 ⁇ m to about 600 ⁇ m, or from about 30 ⁇ m to about 500 ⁇ m, or from about 30 ⁇ m to about 400 ⁇ m, or from about 30 ⁇ m to about 300 ⁇ m, or from about 30 ⁇ m to about 200 ⁇ m, or from about 30 ⁇ m to about 100 ⁇ m, or from about 30 ⁇ m to about 90 ⁇ m, or from about 30 ⁇ m to about 80 ⁇ m, or from about 30 ⁇ m to about 70 ⁇ m, or from about 30 ⁇ m to about 60 ⁇ m, or from about 30 ⁇ m to about 70 ⁇ m, or from
- the base of the microprojections of the present invention may have a thickness of about 5 ⁇ m, or about 10 ⁇ m, or about 15 ⁇ m, or about 20 ⁇ m, or about 25 ⁇ m, or about 30 ⁇ m, or about 35 ⁇ m, or about 40 ⁇ m, or about 45 ⁇ m, or about 50 ⁇ m, or about 55 ⁇ m, or about 60 ⁇ m, or about 65 ⁇ m, or about 70 ⁇ m, or about 75 ⁇ m, or about 80 ⁇ m, or about 85 ⁇ m, or about 90 ⁇ m or about 100 ⁇ m.
- the base of the microprojections of the present invention may have a thickness of from about 5 ⁇ m to about 100 ⁇ m, or from about 5 ⁇ m to about 95 ⁇ m, or from about 5 ⁇ m to about 90 ⁇ m, or from about 5 ⁇ m to about 85 ⁇ m, or from about 5 ⁇ m to about 80 ⁇ m, or from about 5 ⁇ m to about 75 ⁇ m, or from about 5 ⁇ m to about 70 ⁇ m, or from about 5 ⁇ m to about 65 ⁇ m, or from about 5 ⁇ m to about 60 ⁇ m, or from about 5 ⁇ m to about 55 ⁇ m, or from about 5 ⁇ m to about 50 ⁇ m, or from about 5 ⁇ m to about 45 ⁇ m, or from about 5 ⁇ m to about 40 ⁇ m, or from about 5 ⁇ m to about 35 ⁇ m, or from about 5 ⁇ m to about 30 ⁇ m, or from about 5 ⁇ m to about 25 ⁇ m, or from about 5 ⁇ m to about 20 ⁇ m,
- the base of the microprojections of the present invention have a cross sectional length:thickness aspect ratio of about 3:2, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, between 3:2 to 9:1, between 3:2 to 8:1, between 3:2 to 7:1, between 3:2 to 6:1; between 3:2 to 5:1, between 3:2 to 4:1, between 3:2 to 3:1, between 2:1 to 9:1, between 2:1 to 8:1, between 2:1 to 7:1, between 2:1 to 6:1; between 2:1 to 5:1, between 2:1 to 4:1, between 3:1 to 9:1, between 3:1 to 8:1, between 3:1 to 7:1, between 3:1 to 6:1; between 3:1 to 5:1, between 3:1 to 4:1, between 4:1 to 9:1, between 4:1 to 8:1, between 4:1 to 7:1, between 4:1 to 6:1; between 4:1 to 5:1, between 5:1 to 9:1, between 5:1 to 8:1, between 5:1 to 7:1, between 5:1 to 6:1, between 6:1 to 9:1, between 6:1; between
- a high aspect ratio can assist in having the projections penetrate the skin with minimal force.
- puncture is a function of crack formation and subsequent growth.
- the use of a high aspect ratio can assist in allowing cracks to form, thereby reducing the barrier to entry, whilst also maximising the surface area of the projections, which in turn maximises the amount of coating and hence payload that can be delivered. This means that significantly more surface area of the protrusion can enter the skin, without a large increase in energy.
- the height of the microprojections of the present invention depends upon the depth of penetration required.
- the height of the microprojections of the present invention may have a length of from about 30 ⁇ m to about 2 mm, or from about 30 ⁇ m to about 1.5 mm, or from about 30 ⁇ m to about 1 mm, or from about 30 ⁇ m to about 900m, or from about 30 ⁇ m to about 800 ⁇ m, or from about 30 ⁇ m to about 700 ⁇ m, or from about 30 ⁇ m to about 600 ⁇ m, or from about 30 ⁇ m to about 500 ⁇ m, or from about 30 ⁇ m to about 400 ⁇ m, or from about 30 ⁇ m to about 300 ⁇ m, or from about 30 ⁇ m to about 200 ⁇ m, or from about 30 ⁇ m to about 100 ⁇ m, or from about 30 ⁇ m to about 90 ⁇ m, or from about 30 ⁇ m to about 80 ⁇ m, or from about 30 ⁇ m to about 70 ⁇ m, or from about 30 ⁇ m to about 60
- the density of the microprojection on the microprojection arrays may be about 2000 microprojections/cm 2 , or about 2500 microprojections/cm 2 , or about 3000 microprojections/cm 2 , or about 3500 microprojections/cm 2 , or about 4000 microprojections/cm 2 , or about 4500 microprojections/cm 2 , or about 5000 microprojections/cm 2 , or about 5500 microprojections/cm 2 , or about 6000 microprojections/cm 2 , or about 6500 microprojections/cm 2 , or about 7000 microprojections/cm 2 , or about 7500 microprojections/cm 2 , or about 8000 microprojections/cm 2 , or about 8500 microprojections/cm 2 , or about 9000 microprojections/cm 2 , or about 9500 microprojections/cm 2 , or about 10000 microprojections/cm 2 , or about 11000 microprojections/cm 2 , or about 12000 microproject
- the density of the microprojection on the microprojection arrays may be from about 2000 to about 20000 microprojections/cm 2 , or from about 2000 to about 15000 microprojections/cm 2 , or from about to about 10000 microprojections/cm 2 , or from about 2000 to about 9000 microprojections/cm 2 , or from about 2000 to about 8000 microprojections/cm 2 , or from about 2000 to about 7500 microprojections/cm 2 , or from about 2000 to about 7000 microprojections/cm 2 , or from about 2000 to about 6000 microprojections/cm 2 , or from about 2000 to about 5000 microprojections/cm 2 , or from about 2000 to about 4000 microprojections/cm 2 , or from about 3000 to about 20000 microprojections/cm 2 , or from about 3000 to about 15000 microprojections/cm 2 , or from about to about 10000 microprojections/cm 2 , or from about 3000 to about 9000 microprojections/cm 2 ,
- the microprojections of the present invention have a vertical shape that has an extruded base profile with a slight draught angle of approximately 0 to 20 degrees up to a transition point at which point the upper tip of the microprojection will slope towards the tip line at a greater angle.
- the microprojection arrays of the present invention are comprised of a plurality of microprojections.
- the microprojections may be arrayed in lines.
- the spacing between microprojections on a single line may be from about 10 ⁇ m to about 500 ⁇ m, or from about 10 ⁇ m to about 450 ⁇ m or from about 10 ⁇ m to about 400 ⁇ m of from about 10 ⁇ m to about 350 ⁇ m or from about 10 ⁇ m to about 300 ⁇ m or from about 10 ⁇ m to about 250 ⁇ m; or from about 10 ⁇ m to about 200 ⁇ m of from about 10 ⁇ m to about 150 ⁇ m or from about 10 ⁇ m to about 100 ⁇ m or from about 10 ⁇ m to about 50 ⁇ m; or from about 20 ⁇ m to about 500 ⁇ m, or from about 20 ⁇ m to about 450 ⁇ m or from about 20 ⁇ m to about 400 ⁇ m of from about 20 ⁇ m to about 350 ⁇ m or from about 20 ⁇ m to about 300 ⁇ m or from
- the microprojection has a tapering extended hexagonal shape with a rapidly tapering tip at the distal end.
- the microprojections have a spacing of 100 ⁇ m between adjacent lines and 80 ⁇ m between successive microprojections on the array (density about 8000/cm 2 ).
- the tip of the protrusions tapers to a distal line of approximately 25 ⁇ m long and 1-2 ⁇ m wide.
- a gas jet coating process may be used to deposit liquid vaccine material in the coating solution onto the projection array.
- the process parameters i.e. jet angle, jet velocity, solution viscosity, etc.
- coating of the liquid material to the projections can be further enhanced by modifying the surface properties of the projections relative to the liquid coating material.
- the coating may be applied using a gas jet coating technique as described in WO/2009/079712.
- the microprojection arrays of the present invention may penetrate further into the skin than corresponding arrays with conical or cylindrical microprojections having the same length and delivered with the same energy.
- the microprojection arrays of the present invention may penetrate further by 10% or 20% or 30% or 40% or 50% or 60% or 70% or 80% or 90% or 100%.
- the microprojection arrays of the present invention may penetrate further by 10% to 200% or from 10% to 150% or from 10% to 100% or from 10% to 90% or from 10% to 80% or from 10% to 70% or from 10% to 60% or from 10% to 50% or from 10% to 40% or from 10% to 30% or from 10% to 20% or from 20% to 200% or from 20% to 150% or from 20% to 100% or from 20% to 90% or from 20% to 80% or from 20% to 70% or from 20% to 60% or from 20% to 50% or from 20% to 40% or from 20% to 30% or from 30% to 200% or from 30% to 150% or from 30% to 100% or from 30% to 90% or from 30% to 80% or from 30% to 70% or from 30% to 60% or from 30% to 50% or from 30% to 40% or from 40% to 200% or from 40% to 150% or from 40% to 100% or from 40% to 90% or from 40% to 80% or from 40% to 70% or from 40% to 60% or from 40% to 50% or from 50%
- the microprojection arrays of the present invention may provide greater cell death in the cells surrounding the microprojections in the skin than corresponding arrays with conical or cylindrical microprojections having the same length and delivered with the same energy.
- the microprojection arrays of the present invention may provide cell death that is 10% or 20% or 30% or 40% or 50% or 60% or 70% or 80% or 90% or 100% greater.
- the microprojection arrays of the present invention may provide greater cell death by 10% to 200% or from 10% to 150% or from 10% to 100% or from 10% to 90% or from 10% to 80% or from 10% to 70% or from 10% to 60% or from 10% to 50% or from 10% to 40% or from 10% to 30% or from 10% to 20% or from 20% to 200% or from 20% to 150% or from 20% to 100% or from 20% to 90% or from 20% to 80% or from 20% to 70% or from 20% to 60% or from 20% to 50% or from 20% to 40% or from 20% to 30% or from 30% to 200% or from 30% to 150% or from 30% to 100% or from 30% to 90% or from 30% to 80% or from 30% to 70% or from 30% to 60% or from 30% to 50% or from 30% to 40% or from 40% to 200% or from 40% to 150% or from 40% to 100% or from 40% to 90% or from 40% to 80% or from 40% to 70% or from 40% to 60% or from 40% to 50% or from 50% to 200% or from 40% to 150% or from 40% to 100% or from 40% to 90% or from 40% to 80% or from 40% to 70% or from 40% to 60%
- the microprojection arrays of the present invention may provide increased immunogenicity as compared to intramuscular administration of vaccine.
- the microprojection arrays of the present invention may provide increased immunogenicity as compared to corresponding arrays with conical or cylindrical microprojections having the same length and delivered with the same energy in delivering vaccines.
- the microprojection arrays of the present invention may provide an increased immunogenic response by 10% or 20% or 30% or 40% or 50% or 60% or 70% or 80% or 90% or 100%.
- the microprojection arrays of the present invention may provide an increased immunogenic response by 10% to 200% or from 10% to 150% or from 10% to 100% or from 10% to 90% or from 10% to 80% or from 10% to 70% or from 10% to 60% or from 10% to 50% or from 10% to 40% or from 10% to 30% or from 10% to 20% or from 20% to 200% or from 20% to 150% or from 20% to 100% or from 20% to 90% or from 20% to 80% or from 20% to 70% or from 20% to 60% or from 20% to 50% or from 20% to 40% or from 20% to 30% or from 30% to 200% or from 30% to 150% or from 30% to 100% or from 30% to 90% or from 30% to 80% or from 30% to 70% or from 30% to 60% or from 30% to 50% or from 30% to 40% or from 40% to 200% or from 40% to 150% or from 40% to 100% or from 40% to 90% or from 40% to 80% or from 40% to 70% or from 40% to 60% or from 40% to 50% or from 50% to 200% or from 40% to 150% or from 40% to 100% or from 40% to 90% or from 40% to 80% or from 40% to 70% or from 40%
- microprojection arrays of the present invention provide a greater immunogenic response allows the microprojection arrays to deliver a lesser amount of vaccine to achieve the appropriate response as compared to intramuscular or intradermal administration by a needle.
- the ability of the microprojection arrays of the present invention to provide a greater immunogenic response allows the microprojection arrays to deliver a lesser amount of vaccine to achieve the appropriate response as compared to corresponding arrays with conical or cylindrical microprojection.
- Such “dose-sparing” benefit of the microprojection arrays permits a lesser amount of vaccine to be used in each dose to achieve the same immunogenic response.
- the amount of vaccine used with the microprojection arrays of the present invention may be 0.01%, 0.05%, 0.10%, 0.50%, 1%, 5% or 10% or 20% or 30% or 40% or 50% or 60% or 70% or 80% or 90% less than the amount of vaccine used in conventional vaccine administrations.
- the amount of vaccine used with the microprojection arrays of the present invention may be about 0.01% to 90% or from 0.01% to 80% or from 0.01% to 70% or from 0.01% to 60% or from 0.01% to 50% or from 0.01% to 40% or from 0.01% to 30% or from 0.01% to 20% or from 0.01% to 10% or from 0.01% to 1% or from 0.01% to 0.10% or from 0.05% to 90% or from 0.05% to 80% or from 0.05% to 70% or from 0.05% to 60% or from 0.05% to 50% or from 0.05% to 40% or from 0.05% to 30% or from 0.05% to 20% or from 0.05% to 10% or from 0.05% to 1% or from 0.05% to 0.10% or from 0.10% to 90% or from 0.10% to 80% or from 0.10% to 70% or from 0.10% to 60% or from 0.10% to 50% or from 0.10% to 40% or from 0.10% to 30% or from 0.10% to 20% or from 0.10% to 10% or from 0.10% to 1% or from
- the amount of vaccine antigen given per dose may be from about 1 ng, 5 ng, 10 ng, 20 ng, 30 ng, 40 ng, 50 ng, 60 ng, 70 ng, 80 ng, 90 ng, 100 ng, 250 ng, 500 ng, 750 ng, 1 ⁇ g dose, 2 ⁇ g dose, 3 ⁇ g dose, 4 ⁇ g dose, 5 ⁇ g dose, 6 ⁇ g dose, 7 ⁇ g dose, 8 ⁇ g dose, 9 ⁇ g dose, 10 ⁇ g dose, 15 ⁇ g dose, 20 ⁇ g dose, 25 ⁇ g dose, 30 ⁇ g, 40 ⁇ g dose, 50 ⁇ g dose, 60 ⁇ g dose, 70 ⁇ g dose, 80 ⁇ g dose may be sufficient to induce an immune response.
- the dose of vaccine antigen may be administered to the human within a range of doses including from about 1 ng to about 10 ⁇ g, about 1 ng to about 5 ⁇ g, about 1 ng to about 1 ⁇ g, about 1 ng to about 900 ng, about 1 ng to about 800 ng, about 1 ng to about 700 ng, about 1 ng to about 600 ng, about 1 ng to about 500 ng, about 1 ng to about 400 ng, about 1 ng to about 300 ng, about 1 ng to about 200 ng, about 1 ng to about 100 ng about 1 ng to about 75 ng, about 1 ng to about 50 ng, about 1 ng to about 25 ng, about 10 ng to about 10 ⁇ g, about 10 ng to about 5 ⁇ g, about 10 ng to about 1 ⁇ g, about 10 ng to about 900 ng, about 10 ng to about 800 ng, about 10 ng to about 700 ng, about 10 ng to about 600 ng, about 10 ng to about
- the microprojection array may be applied vertically, laterally or a combination thereof. A lateral application of the microprojection array will slide the microprojections along the surface of the skin to penetrate the skin in lanes.
- the applicators of the present invention utilize a ‘low-force, higher velocity’ applicator which may use a “flying” microprojection array in which the microprojection array is discharged from the device with sufficient force to propel the array through space and into the skin. Peak stresses are associated with the penetration of projections, without the follow-through, and the higher velocity achieves the change of behavior of the skin from elastic to plastic.
- the use of low force, high velocity approach to penetration of the skin by the microprojection array provides advantages such as: achieving equivalent penetration in the skin, but with about only 1/10 th the Kinetic Energy; improved patient acceptability/tolerability of the penetration of the skin by the microprojection array and significantly less breakage of projections (up to about 1/10000 reduction of breakage) and patch base.
- the use of low force, high velocity application of the microprojection array to the skin also provides consistent penetration of the patch from site to site, because the mechanics of penetration are not heavily reliant on variations of the subcutaneous tissue (which does vary significantly within and individual and between people in populations).
- the direct correlation of kinetic energy with penetration may be utilized to design an applicator and microarray projections that provides maximal efficiency in delivering material to the patient while reducing discomfort to the patient.
- the speed of the microprojection array as it is projected into the skin depends at least in part upon the density of the projections in the microarray and the area of the array.
- the range of speeds for the microprojection array entering the skin may be from about 5 m/s to about 50 m/s or from about 5 m/s to about 40 m/s or from about 5 m/s to about 30 m/s or from about 5 m/s to about 25 m/s or from about 5 m/s to about 20 m/s or about 10 m/s to about 50 m/s or from about 10 m/s to about 40 m/s or from about 10 m/s to about 30 m/s or from about 10 m/s to about 25 m/s or from about 10 m/s to about 20 m/s or from about 20 m/s to about 50 m/s or from about 20 m/s to about 40 m/s or from about 20 m/s to about 30 m/s or from about 25
- the microprojections have a tapering extended hexagonal shape with a rapidly tapering tip at the distal end.
- the protrusions have a spacing of 100 ⁇ m between adjacent lines and 80 ⁇ m between successive protrusions (density about 8000/cm 2 ).
- the tip of the protrusions tapers to a distal line of approximately 25 ⁇ m long and 1-2 ⁇ m wide.
- FIGS. 5 A- 5 B An example of a microprojection array 500 is shown in FIGS. 5 A- 5 B .
- the microprojection array 500 comprises a substrate 520 with a plurality of microprojections 510 protruding from the substrate 520 .
- the microprojection array 500 includes microprojections 510 arranged in a number of straight, spaced apart lines as shown in FIG. 5 B .
- S 1 the spacing of the microprojections 510 between adjacent lines
- S 2 the spacing between successive microprojections 510 in the same line.
- the microprojections 510 have a tapering hexagonal shape and comprise a tip 611 and a base 612 wherein the base 612 has two substantially parallel sides 621 , 622 with a slight draught angle of approximately 1 to 20 degrees (as indicated in FIG. 6 B by ⁇ 1 ) up to a transition point 613 at which point the angle increases to from about 20 degrees to about 70 degrees (as indicated in FIG. 6 B by ⁇ 2 ).
- this example depicts a distinct increase in the angle at the transition point 613 , it should be noted that there may be a more gradual increase in the angle than depicted.
- each microprojection 510 terminates in an elongate edge.
- the tip 611 has a width W tip and a length L tip .
- the base 612 has a length L base , and is greater in length than the tip 611 .
- the base 612 has a thickness T base .
- the cross sectional length:thickness aspect ratio of the base 612 is defined as L base :T base , and is greater than 2:1 in this case.
- Each microprojection has an overall height H which depends upon the depth of penetration required.
- the present invention relates to microarray projections which are designed to have a large surface area to frontal profile design while maintaining a high density configuration.
- the microprojection arrays of the present invention exploit the manner in which skin punctures. On a micro-scale, puncture is a function of crack formation in the skin and the subsequent growth of these cracks. While high density microneedles or microdevices perform this in a large number for every individual “needle”, it necessitates a very large number of crack initiations thereby absorbing substantial energy.
- the devices of the present invention use a lower density of protrusions compared to some high density arrays, which have a line of contact rather than a single contact point.
- the protrusion will easily enter the skin, allowing internal skin surface area contact with penetrating surface. This means that significantly more surface area for the protrusion to enter the skin.
- the microprojections of the present invention may be wider and thinner than current conically or cylindrically shaped microprojections. Thus, a single line of contact may cut into the skin rather than point punctures. The results are that a larger surface may be introduced into the skin rather than individual points penetrating the skin in which each point must be opened before vaccine may be delivered.
- the present invention relates to microprojection arrays where the microprojection design provides an alternative mode of skin puncture and vaccine delivery into the skin.
- the microprojections of the present invention are designed to have a large surface area to frontal profile design while maintaining a high density of microprojections on the array.
- the microprojection arrays of the present invention have a plurality of microprojections that are located upon a base.
- the microprojection have a shape that from a top down perspective is approximately an extended hexagon with two parallel sides being extended to give a rectangular profile with triangular ends.
- the microprojections have a shape that from a top down perspective is approximately an extended octagon. This profile is similar to the hexagonally-shaped microprojection except that the ends of the microprojections are broadened.
- the microprojections may be aligned in parallel line with spacing between the edges of the microprojections.
- the microprojections may extend vertically to a length that will provide for drugs or vaccines to be delivered to the desired location within the skin.
- the present invention relates to microprojections having a tapering extended hexagonal or octagonal shape comprising a base and a tip wherein the tip has a width of from about 0.5 ⁇ m to about 2 ⁇ m and a length of about 10 ⁇ m to about 2 mm.
- the present invention relates to microprojection arrays comprising a plurality of microprojections wherein the microprojections have a tapering extended hexagonal shape or octagonal and comprise a base and a tip wherein the tip has a width of from about 0.5 ⁇ m to about 2 ⁇ m and a length of about 10 ⁇ m to about 2 mm.
- the present invention relates to microprojection arrays comprising a plurality of microprojections organized in lines on the array wherein the microprojections have a tapering extended hexagonal or octagonal shape and wherein the spacing of the microprojection between adjacent lines is 100 ⁇ m and the spacing between successive microprojections is 80 ⁇ m.
- the present invention relates to methods of administering a vaccine to a human comprising applying the microprojection arrays in which vaccine is coated onto the microprojections of the arrays of the present invention to a human's skin.
- the present invention relates to microprojection arrays comprising a substrate with a plurality of microprojections protruding from the substrate wherein the microprojections have a tapering hexagonal or octagonal shape and comprise a tip and a base wherein the base has two substantially parallel sides with a slight draught angle of approximately 1 to 20 degrees up to a transition point at which point the angle increases to from about 20 degrees to about 70 degrees.
- the present invention relates to microprojection arrays where the substrate is solid or non-porous or non-hollow.
- the present invention relates to microprojection arrays where the microprojection array includes a number of microprojections arranged in a line.
- the present invention relates to microprojection arrays where the line is a straight line or a curved line or a circular line extending circumferentially around an axis.
- the present invention relates to microprojection arrays where some of microprojections in a line have a common base.
- the present invention relates to microprojection arrays where the microprojection array includes a number of spaced apart lines.
- the present invention relates to microprojection arrays where the spacing of the microprojections between adjacent lines is less than 200 ⁇ m or less than 150 ⁇ m or about 100 ⁇ m.
- the present invention relates to microprojection arrays where the spacing between successive microprojections is less than 200 ⁇ m or less than 150 ⁇ m or less than 100 ⁇ m or about 80 ⁇ m.
- microprojection arrays were coated in a solution of 1% methylcellulose and the required vaccine dose dissolved in injectable phosphate buffered saline solution (Chen, et al, J. Controlled Release (2009) 139, 212). Fluvax 2014® was used as the antigen. Delivered dose was measured using radioassay (Fernando, et al. PLos One (2010) 5, e10266). Specific pathogen-free female C57BL/6 mice from 6 to 8 weeks old were used in all examples. Groups of 5 mice were use in each Example. Application of all microprojection array patches were performed as described (Crichton et al., Biomaterials (2010) 31, 4562) at a velocity of 2.3 m/s.
- the surface area and volume of the projections entering the skin was calculated upon models using Solid Edge® software (Siemens PLM Software, Texas, US). Imaging of microprojection array puncturing and delivery into the skin was performed by coating the microprojections with Fluorospheres (Molecular Probes, OR, US) and applying the microprojection arrays to skin for histology or excised skin for CryoSEM and imaging as described (3). Trans-Epidermal water loss (TEWL) was measured using a Tewawater® TM300 (Courage & Khazajka Electronic GmbH, Cologne, Germany). Mice had TEWL measurement taken prior to microprojection array application, immediately post- microprojection array application and at 30, 60, 90 and 120 minutes and then every hour from 3-8 hours post application of the microprojection array.
- TEWL Trans-Epidermal water loss
- Lysates were passed through a 70 ⁇ m strainer and cells pelleted by centrifugation with an additional 4U DNAse I treatment. Cells were incubated with purified anti-CD 16/32 (Clone 93, Biolegend, San Diego, CA) for 15 minutes at 4° C. before washing and staining with a cocktail of fluorescently—conjugated anti-mouse monoclonal antibodies for 30 minutes at 4° C.
- CD45.2 PercP Cy5.5 (clone 104), CD11c PECy7 (N418), Ly6C APC (HK1.4RUO) (all from Affymetrix, San Diego, CA) CD11b Brilliant Violet 605 (M1/70), F4/80 Brilliant Vioet 421 (BM8) (Biolegend, San Diego, CA) and Ly6G FITC (IA8), Siglec F PE (E50-2440) (Becton Dickenson, Franklin lakes, NJ). Data were acquired on a BD LSR II flow cytometer and analysed using Flowjo v9 (TreeStar, Ashland, OR). DRAQ 7 (Biostatus, Shepshed UK) was used to exclude dead cells before analysis.
- FIG. 1 shows the microprojections before coating.
- the coating solution is localized around the tips of the microprojections.
- Post-skin application imaging demonstrated that the coating on the tips of the microprojections had been removed and that the microprojections had entered the skin as evidenced by the tide mark on the microprojections' surfaces.
- Both TP and NP microprojections show varied penetration over the array surface indicating the complexity of penetrating a topographically variable skin surface.
- the TP microprojection shows a deeper penetration indicating the full dermis had been penetrated whereas the NP microprojections appear to have penetrated the epidermis and upper dermis. There appears to be a greater overall coverage of delivery by TP when an overhead view is surveyed.
- the minor axis shrinks to 5-10 ⁇ m after an initial width of 20 ⁇ m, a reduction of 50-75%.
- the data indicates much larger residual stress in opening a hole across the major axis as opposed to opening a hole along the major axis.
- This supports the concept that crack growth along the major axis of the microprojection will be the main driver of penetration which can serve to reduce residual stress concentrations along this axis.
- cylindrical or circular holes made by microprojections where the major and minor axis are the same or similar will close from all direction with considerable residual stress from all side of the microprojection. This shape of microprojection provides no stress relief to assist the penetration process.
- Trans-Epidermal Water Loss was measured in skin penetrated by both TP and NP microprojections. The skin penetrated by NP microprojections healed more quickly that skin penetrated by TP microprojections consistent with view that large cracks are formed during TP microprojection penetration.
- the increase penetration of the TP microprojections into the skin results from a greater ability to penetrate the skin rather than the disproportionate volume or surface area penetrating into the skin at comparable depths.
- the increase volume of the TP microprojections indicates easier entry into the skin which appears to be due to fewer penetrating microprojection into the skin and microprojections expanding punctures through the skin surface.
- TP microprojection array Five ng of commercial influenza vaccine (Fluvax®) was administered to pathogen-free female C57BL/6 mice from 6 to 8 weeks old using intradermal injection, administration of NP microprojection array, administration of NP microprojection array, or intramuscular injection. The results are shown in FIG. 3 .
- the immune response to the TP microprojection array which held 5 ng of antigen was equivalent to the NP microprojection array response to 50 ng of antigen which indicates a 10 fold increase in immunogenicity by altering the shape and dimensions of the microprojections.
- the increased immunogenicity exhibited by the TP microprojection array is similar to the inclusion of a chemical adjuvant using the NP microprojection array.
- TP microprojection array in delivering 50 ng of vaccine proved to a potent immune enhancer more than doubling the IgG titer of the elicited by the NP at the same dose (as shown in FIGS. 3 and 4 ).
- TP and NP microprojection arrays were applied to mouse ears and the skin stained for necrotic cell death and then imaged using confocal microscopy. An example of such an image is shown in FIG. 2 .
- cell death was observed within a radius of 20-30 ⁇ m with a greater number of dead cells on the edge of the array where bridged vaccine formulation restricted penetration but allowed significant force transmission into the skin.
- dead cells are observed primarily along the major axis of the microprojections. These extend approximately 5 -25 ⁇ m from the centerline of the microprojections indicating that this area is the area of highest stress upon insertion of the array.
- the level of cell death results in an increased level of inflammation throughout the tissue which may be a stimulating factor for an enhanced immune response.
- the number of neutrophils and macrophages after administration of the TP array increased as opposed to the NP array.
- monocytes and eosinophils There also was a trend toward an increase in monocytes and eosinophils as well.
- the inflamed microenvironment may give an improved environment for dendritic cells to uptake vaccine and subsequently enhance immunogenicity.
- Ranges may be expressed herein as from about one particular value, and/or to about another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent about, it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.
- any indication that a feature is optional is intended provide adequate support (e.g., under 35 U.S.C. 112 or Art. 83 and 84 of EPC) for claims that include closed or exclusive or negative language with reference to the optional feature.
- Exclusive language specifically excludes the particular recited feature from including any additional subject matter. For example, if it is indicated that A can be drug X, such language is intended to provide support for a claim that explicitly specifies that A consists of X alone, or that A does not include any other drugs besides X. “Negative” language explicitly excludes the optional feature itself from the scope of the claims.
- Non-limiting examples of exclusive or negative terms include “only,” “solely,” “consisting of,” “consisting essentially of,” “alone,” “without”, “in the absence of (e.g., other items of the same type, structure and/or function)” “excluding,” “not including”, “not”, “cannot,” or any combination and/or variation of such language.
- a dog is intended to include support for one dog, no more than one dog, at least one dog, a plurality of dogs, etc.
- qualifying terms that indicate singularity include “a single”, “one,” “alone”, “only one,” “not more than one”, etc.
- qualifying terms that indicate (potential or actual) plurality include “at least one,” “one or more,” “more than one,” “two or more,” “a multiplicity,” “a plurality,” “any combination of,” “any permutation of,” “any one or more of,” etc.
Abstract
A microprojection array comprising a substrate with a plurality of microprojections protruding from the substrate wherein the microprojections have a tapering hexagonal shape and comprise a tip and a base wherein the base has two substantially parallel sides with a slight draught angle of approximately 1 to 20 degrees up to a transition point at which point the angle increases to from about 20 degrees to about 70 degrees.
Description
- The invention is generally directed to devices and methods for intradermal delivery of active agents into the skin, more particularly, the invention is directed to devices and methods for improving the immunogenicity of vaccine preparations by intradermal delivery of the vaccine via a microprojection array in which the geometry of the projections have been designed to improve skin penetration.
- In recent years, attempts have been made to devise new methods of delivering drugs and other bioactive materials, for vaccination and other purposes, which provide alternatives that are more convenient and/or enhanced in performance to the customary routes of administration such as intramuscular and intradermal injection. Limitations of injection include: cross-contamination through needle-stick injuries in health workers; injection phobia from a needle and syringe; and most importantly, as a result of its comparatively large scale and method of administration, the needle and syringe cannot target key cells in the outer skin layers. This is a serious limitation to many existing and emerging strategies for the prevention, treatment and monitoring of a range of untreatable diseases.
- In response to the problems of needle and syringe, multiple devices and methods were developed to deliver active agents intradermally. Depending on the device the desired active agent can be applied either as a liquid formulation or as solid, powdered vaccine particles. The process of intradermal injection employs micron-sized needles that are inserted 1.5 mm perpendicularly into the skin, and which inject approximately 100-200 μl of a liquid vaccine formulation into the dermal skin layers. Microneedle arrays are made of coated solid microneedles or biodegradable microneedles. These are inserted into the dermal layers of the skin where either the coating is dissolved, or the microneedle itself dissolves in place.
- In particular, the delivery of vaccines intradermally has presented challenges as the question of the ideal immune targeting location in the skin remains the subjection of debate. For example, Langerhans cells in the viable epidermis were considered to be immune cells until recently, however the prevailing thought is that these cells are tolerogenic (Romani, et al., J. Invest. Dermatol (2012) 132, 872). Intradermal injection is routinely shown to elicit strong immune responses and microprojection arrays such as the Nanopatch™ have demonstrated that reduced dosing utilizing these devices may be as effective as large dose intramuscular injection (Fernando, et al. PLos One (2010) 5, e10266). In addition to questions surrounding the ideal immune targeting location in the skin, the level of cellular/tissue damage caused by microprojection arrays is also an issue. This damage may be a large contributing factor to the immune response and the appropriate level of damage is an issue that is being explored. The mechanism of delivery of microprojection arrays to the skin also affects the level of cellular/tissue damage caused by microprojection arrays. Finally, due to the disparity in the mechanical modulus of the skin's constituent layers precise delivery of microprojection arrays to a targeted depth in the skin can be challenging.
- There have been various approaches to optimizing the microneedle arrays and the methods by which they are made. Ceyssens et al., Fabrication process for tall, sharp, hollow high aspect ratio polymer microneedles on a platform, J. Micromech. and Microeng. 23 (2013) 075023 describes a process based on a combination of molding and UV lithography yielding hollow needles with record aspect ratio and sharpness that are monolithic with a platform, and feature a maximum needle length of over one millimeter while at the same time being suitable for mass fabrication. US Patent Publication No. 2009/0292254 disclose biocompatible and biodegradable microneedles having various shapes and geometries. U.S. Pat. No. 7,497,980 describes the manufacture of moulds for microneedles arrays are triangular as well as pyramidal and include microneedles that are solid as well as those through which a channel courses or those with grooves carved therein. U.S. Pat. No. 7,591,806 describes microblades or microdevices that are used as biological delivery devices that will puncture the skin. U.S. Pat. No. 6,537,264 discloses blade-type microneedles that are used to sample bodily fluids. US Patent Publication No. 2007/0293815 discloses microprojection arrays for penetrating the skin and delivering a vaccine. U.S. Pat. No. 8,414,548 describes microneedles that are formed from cutting metal with a laser and then bending the metal to form the microneedles. Prausnitz, M. R., Coated Microneedles for Transdermal Delivery, J. Controlled Release Soc. 117.2 (2007) 227-237 describe the use of sheet metal to fashion microneedles. US Patent Publication No. 2011/0021996 describes a microneedle array in which the microneedles have a conduit through which an active substance can be inserted into a body through the skin.
- High density arrays require more energy to penetrate the skin than lower density arrays and thus modification to the shape, structure and geometry of the microprojections may be required to generate an efficient skin puncture that permits penetration of the microprojections to a greater depth within the skin. Therefore, there is a need to construct microprojection arrays with appropriate microprojection geometry coupled with an understanding of the mechanical parameters of vaccine placement, skin puncture and mechanically induced cellular damage so that a more efficient system of delivering vaccine to the skin may be provided. The microprojection arrays of the present invention provide devices with greater vaccine loading and delivery than previous designs with more precise targeting within the skin.
- The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that the prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
- In a broad form the present invention seeks to provide a microprojection array comprising a substrate with a plurality of microprojections protruding from the substrate wherein the microprojections have a tapering hexagonal shape and comprise a tip and a base wherein the base has two substantially parallel sides with a slight draught angle of approximately 1 to 20 degrees up to a transition point at which point the angle increases to from about 20 degrees to about 70 degrees.
- Typically the substrate is at least one of:
-
- a) solid;
- b) non-porous; and
- c) non-hollow.
- Typically the microprojection array includes a number of microprojections arranged in a line.
- Typically the line is at least one of:
-
- a) a straight line;
- b) a curved line; and,
- c) a circular line extending circumferentially around an axis.
- Typically at least some of the microprojections in a line have a common base.
- Typically the microprojection array includes a number of spaced apart lines.
- Typically the spacing of the microprojections between adjacent lines is at least one of:
-
- a) less than 200 μm;
- b) less than 150 μm; and,
- c) about 100 μm.
- Typically the spacing between successive microprojections is at least one of:
-
- a) less than 200 μm;
- b) less than 150 μm;
- c) less than 100 μm; and,
- d) about 80 μm.
- Typically the tip of each microprojection terminates in an elongate edge.
- Typically the tip has a width of from about 1 μm to about 2 μm and a length of about 20 μm to about 2 mm
- Typically the tip has a width of about 1 μm and a length of about 20 μm.
- Typically the base has a length of from about 30 μm to about 2 mm.
- Typically the base has a length of about 80 μm.
- Typically the base is greater in length than the tip.
- Typically the base has a thickness of about 5 μm to 50 μm.
- Typically the base has a cross sectional length:thickness aspect ratio of about 2:1 to 5:1.
- Typically at least one of the microprojections is coated with a vaccine antigen.
- Typically the amount of the vaccine antigen is about 10 ng to about 10 μm.
- Typically the amount of vaccine antigen is about 10% to about 50% less than the amount of vaccine antigen delivered by intramuscular administration.
- Typically the administration of the vaccine antigen provides a greater immunogenic response when administered to a human than a comparable amount of vaccine antigen administered by intramuscular injection.
- Typically the administration of the vaccine antigen provides a greater immunogenic response when administered to a human than a comparable amount of vaccine antigen administered with a microprojection array with conical or cylindrical microprojections.
- Typically the microprojections have an effective cross-sectional area which is unchanged by the addition of the coating.
- In another broad form the present invention seeks to provide a method of administering a vaccine to a human comprising applying the microprojection array as described above to a human's skin.
- Typically the microprojection array includes a number of microprojections arranged in a line, and wherein the method includes applying the microprojection array to a human's skin in a direction of movement including a component of movement aligned with the line.
- Typically the line is a straight line and the method includes applying the microprojection array to the skin in a direction perpendicular to the skin and laterally parallel to the skin in the direction of the line.
- Typically the line extends circumferentially around an axis and the method includes applying the microprojection array to the skin in a direction perpendicular to the skin whilst rotating the microprojection array around the axis.
- In yet another broad form the present invention seeks to provide a microprojection array comprising a substrate with a plurality of microprojections protruding from the substrate wherein the microprojections have a tapering octagonal shape and comprise a tip and a base wherein the base has two substantially parallel sides with a slight draught angle of approximately 1 to 20 degrees up to a transition point at which point the angle increases to from about 20 degrees to about 70 degrees.
- Typically the substrate is at least one of:
-
- a) solid;
- b) non-porous; and
- c) non-hollow.
- Typically the microprojection array includes a number of microprojections arranged in a line.
- Typically the line is at least one of:
-
- a) a straight line;
- b) a curved line; and,
- c) a circular line extending circumferentially around an axis.
- Typically at least some of the microprojections in a line have a common base.
- Typically the microprojection array includes a number of spaced apart lines.
- Typically the spacing of the microprojections between adjacent lines is at least one of:
-
- a) less than 200 μm;
- b) less than 150 μm; and,
- c) about 100 μm.
- Typically the spacing between successive microprojections is at least one of:
-
- a) less than 200 μm;
- b) less than 150 μm;
- c) less than 100 μm; and,
- d) about 80 μm.
- Typically the tip of each microprojection terminates in an elongate edge.
- Typically the tip has a width of from about 1 μm to about 2 μm and a length of about 20 μm to about 2 mm.
- An example of the present invention will now be described with reference to the accompanying drawings, in which:
-
FIG. 1 is an SEM image of one embodiment of uncoated microprojections of the present invention; -
FIG. 2 is an image of skin stained to show live (green) and dead (magenta) cells following administration of one embodiment of microprojections of the present invention; -
FIG. 3 is a plot of anti-Influenza antibody levels of sera from C57BL/6 mice determined by indirect ELISA plotted as 50% titers; -
FIG. 4 is a plot of day 21 IgG Titers for 5 ng, 50 ng and 500 ng influenza doses administered intramuscularly, intradermally and by microprojection array TP and NP; -
FIG. 5A is a schematic plan view of an example of a microprojection array; -
FIG. 5B is a schematic front view of a line of microprojections of the microprojection array; -
FIG. 6A is a schematic front view of an example of a microprojection; -
FIG. 6B is a schematic side view of the microprojection; and, -
FIG. 6C is a schematic plan view of the microprojection. - The present invention relates to microprojection arrays where the microprojection design provides an alternative mode of skin puncture and vaccine delivery into the skin. The microprojections of the present invention are designed to have a large surface area to frontal profile design while maintaining a high density of microprojections on the array. The microprojection arrays of the present invention have a plurality of microprojections that are located upon a base. In one embodiment the microprojection have a shape that from a top down perspective is approximately an extended octagon. In another embodiment the microprojections have a shape that from a top down perspective is approximately an extended hexagon with two parallel sides being extended to give a rectangular profile with triangular ends (
FIG. 1 ). The microprojections may be aligned in parallel lines with spacing between the edges of the microprojections. The microprojections may extend vertically to a length that will provide for drugs or vaccines to be delivered to the desired location within the skin. The microprojections of the microprojection arrays of the present invention may be solid or non-porous or contain hollow portions therein. In some embodiments the microprojections are solid and non-porous and do not contain any hollow portion therein. In preferred embodiments the devices of the present invention do not contain reservoirs. - At least a portion of the projections may be coated. Accordingly, one way of providing material for delivery to the biological subject is by providing the material within the coating. For example, the coating may include a vaccine for providing an immunological response within the subject. The coating may be provided in liquid or non-liquid forms, and may further include ingredients other than the material to be delivered, such as an adjuvant. Suitable coating formulations for use with projections patches and methods of applying such coatings to the projections are known, as described, for example, in WO/2010/042996 and WO/2009/079712.
- Although any type of coating may be used, particularly advantageous embodiments of the microprojection arrays are provided with at least a portion of the projections coated with a non-liquid coating. In this regard, the term “non-liquid” coating will be understood to include a coating that is applied in a liquid form and allowed to dry or otherwise solidify to thereby form a non-liquid coating.
- The non-liquid coating may act as an additional substantially solid layer of material which can be used to even further adjust the geometry of the projections by optionally causing the projections to have an effective profile of a different shape to the underlying uncoated profile of the projections as initially fabricated.
- The microprojections of the present invention are less sensitive to coating thickness as it relates to skin penetration. In a standard conical projection the thickness of the coating affects the cross-sectional area of the microprojection thereby affecting the ability of the microprojection to penetrate the skin at a given velocity. In the microprojections of the present invention the effective cross-sectional area is little changed by the addition of the coating, thus the velocity required for skin penetration is relatively constant.
- The microprojection arrays have a substrate with a plurality of microprojections protruding from the substrate wherein the microprojections have a tapering hexagonal shape and comprise a tip and a base wherein the base has two substantially parallel sides with a slight draught angle of approximately 1 to 20 degrees up to a transition point at which point the angle increases to from about 20 degrees to about 70 degrees. In an alternate embodiment the ends of the microprojections may be blunted to provide an extended octagonal profile. While the profiles of the microprojections of the present invention may define extended hexagonal or octagonal shapes the edges of the profiles may be somewhat rounded depending on the method of manufacture of the microprojections and microprojection arrays.
- The draught angle may be between about 0 to 30 degrees or about 0 to 25 degrees or about 0 to 20 degrees or about 0 to 15 degrees or about 0 to 10 degrees, or about 1 to 30 degrees or about 1 to 25 degrees or about 1 to 20 degrees or about 1 to 15 degrees or about 1 to 10 degrees, or about 2 to 30 degrees or about 2 to 25 degrees or about 2 to 20 degrees or about 2 to 15 degrees or about 2 to 10 degrees, about 3 to 30 degrees or about 3 to 25 degrees or about 3 to 20 degrees or about 3 to 15 degrees or about 3 to 10 degrees, about 4 to 30 degrees or about 4 to 25 degrees or about 4 to 20 degrees or about 4 to 15 degrees or about 4 to 10 degrees, or about 5 to 30 degrees or about 5 to 25 degrees or about 5 to 20 degrees or about 5 to 15 degrees or about 5 to 10 degrees.
- The transition point angle may be between about 20 to 70 degrees or about 20 to 65 degrees or about 20 to 60 degrees or about 20 to 55 degrees or about 20 to 50 degrees, or about 20 to 45 degrees or about 20 to 40 degrees or about 20 to 35 degrees or about 20 to 30 degrees or about 20 to 25 degrees, about 25 to 70 degrees or about 25 to 65 degrees or about 25 to 60 degrees or about 25 to 55 degrees or about 25 to 50 degrees, about 25 to 45 degrees or about 25 to 45 degrees or about 25 to 40 degrees or about 25 to 35 degrees or about 25 to 30 degrees, or about 30 to 70 degrees or about 30 to 65 degrees or about 30 to 60 degrees or about 30 to 55 degrees or about 30 to 50 degrees or about 30 to about 45 degrees or about 30 to about 40 degrees or about 30 to about 35 degrees. In preferred embodiments the transition point angle will be greater than the draught angle.
- A sharp blade-like tip will allow for enhanced penetration of the microprojections into the skin while also generating an enhanced localized cell death/bystander interaction in the skin with a different profile than conical microprojection arrays. The sharp blade-like tips of the microprojections may also increase the level of danger signals and antigen to more live cells thereby increasing the physical adjuvant effect of microprojections and thereby improving immune responses. On a micro-scale, skin puncture is a function of crack formation in the skin and the subsequent expansion of these cracks. While high density microprojection arrays have each individual microprojection initiating a crack (which absorbs substantial energy), the microprojection arrays of the present invention provide a line of contact rather than a single point of contact. Thus, once the crack begins to form the microprojections may enter the skin more easily allowing internal skin surface area contract with the penetrating surface. Significantly more surface area of the protrusion can enter the skin without a large increase in energy. The microprojection profile of the microprojection arrays of the present invention is wider and thinner than current conical or circular microprojection profiles. The microprojection arrays of the present invention reduce the number of penetrations made upon entry to the skin, increase the area of the microprojection in the skin and exploit surface crack propagation to enhance overall penetration and reduce the overall energy required to puncture the skin. The microprojection array may be delivered to the skin surface by an applicator. Due to the unique design of the microprojections of the present invent invention the amount of energy required to penetrate the skin will be much less than that of other microprojection arrays. The microprojection arrays may be delivered by direct vertical application onto skin or a lateral movement on skin which will allow the blades of the microprojections to cut the skin.
- While penetration of the skin by microprojections causes cell death, the microprojection arrays of the present invention provide a higher level of cell death per projection than the standard conical microprojection and generate significantly improved immune responses compared to the standard conical microprojection. Therefore, the microprojections of the present invention provide an increased and controlled physical adjuvantation effect in the skin thereby significantly improving immunogenicity.
- The tip of the microprojections of the present invention may have a width of about 0.5 μm, or about 1.0 μm, or about 1.5 μm, or about 2.0 μm, or about 2.5 μm, or about 3.0 μm, or about 3.5 μm, or about 4.0 μm, or about 4.5 μm, or about 5.0 μm. The tip of the microprojections of the present invention may have a width of from about 0.5 μm to about 5.0 μm, or from about 0.5 μm to about 4.5 μm, or from about 0.5 μm to about 4.0 μm, or from about 0.5 μm to about 3.5 μm, or from about 0.5 μm to about 3.0 μm, or from about 0.5 μm to about 2.5 μm, or from about 0.5 μm to about 2.0 μm, or from about 0.5 μm to about 1.5 μm, or from about 0.5 μm to about 1.0 μm, or from about 1.0 μm to about 5.0 μm, or from about 1.0 μm to about 4.5 μm, or from about 1.0 μm to about 4.0 μm, or from about 1.0 μm to about 3.5 μm, or from about 1.0 μm to about 3.0 μm, or from about 1.0 μm to about 2.5 μm, or from about 1.0 μm to about 2.0 μm, or from about 1.0 μm to about 1.5 μm, or from about 1.5 μm to about 5.0 μm, or from about 1.5 μm to about 4.5 μm, or from about 1.5 μm to about 4.0 μm, or from about 1.5 μm to about 3.5 μm, or from about 1.5 μm to about 3.0 μm, or from about 1.5 μm to about 2.5 μm, or from about 1.5 μm to about 2.0 μm, or from about 2.0 μm to about 5.0 μm, or from about 2.0 μm to about 4.5 μm, or from about 2.0 μm to about 4.0 μm, or from about 2.0 μm to about 3.5 μm, or from about 2.0 μm to about 3.0 μm, or from about 2.0 μm to about 2.5 μm, or from about 2.5 μm to about 5.0 μm, or from about 2.5 μm to about 4.5 μm, or from about 2.5 μm to about 4.0 μm, or from about 2.5 μm to about 3.5 μm, or from about 2.5 μm to about 3.0 μm.
- The tip of the microprojections of the present invention may have a length of about 20 μm, or about 30 μm, or about 40 μm, or about 50 μm, or about 60 μm, or about 70 μm, or about 80 μm, or about 90 μm, or about 100 μm, or about 150 μm, or about 200 μm, or about 250 μm, or about 500 μm, or about 1000 μm, or about 1500 μm, or about 2000 μm. The tip of the microprojections of the present invention may have a length of from about 10 μm to about 2 mm, or from about 10 μm to about 1.5 mm, or from about 10 μm to about 1 mm, or from about 10 μm to about 900 μm, or from about 10 μm to about 800 μm, or from about 10 μm to about 700 μm, or from about 10 μm to about 600 μm, or from about 10 μm to about 500 μm, or from about 10 μm to about 400 μm, or from about 10 μm to about 300 μm, or from about 10 μm to about 200 μm, or from about 10 μm to about 100 μm, or from about 10 μm to about 90 μm, or from about 10 μm to about 80 μm, or from about 10 μm to about 70 μm, or from about 10 μm to about 60 μm, or from about 10 μm to about 70 μm, or from about 10 μm to about 60 μm, or from about 10 μm to about 50 μm, or from about 10 μm to about 40 μm, or from about 10 μm to about 30 μm, or from about 10 μm to about 20 μm, or from about 20 μm to about 2 mm, or from about 20 μm, to about 1.5 mm, or from about 20 μm to about 1 mm, or from about 20 μm to about 900 μm, or from about 20 μm to about 800 μm, or from about 20 μm to about 700 μm, or from about 20 μm to about 600 μm, or from about 20 μm to about 500 μm, or from about 20 μm to about 400 μm, or from about 20 μm to about 300 μm, or from about 20 μm to about 200 μm, or from about 20 μm to about 100 μm, or from about 20 μm to about 90 μm, or from about 20 μm to about 80 μm, or from about 20 μm to about 70 μm, or from about 20 μm to about 60 μm, or from about 20 μm to about 70 μm, or from about 20 μm to about 60 μm, or from about 20 μm to about 50 μm, or from about 20 μm to about 40 μm, or from about 20 μm to about 30 μm, about 30 μm to about 2 mm, or from about 30 μm to about 1.5 mm, or from about 30 μm to about 1 mm, or from about 30 μm to about 900 μm, or from about 30 μm to about 800 μm, or from about 30 μm to about 700 μm, or from about 30 μm to about 600 μm, or from about 30 μm to about 500 μm, or from about 30 μm to about 400 μm, or from about 30 μm to about 300 μm, or from about 30 μm to about 200 μm, or from about 30 μm to about 100 μm, or from about 30 μm to about 90 μm, or from about 30 μm to about 80 μm, or from about 30 μm to about 70 μm, or from about 30 μm to about 60 μm, or from about 30 μm to about 70 μm, or from about 30 μm to about 60 μm, or from about 30 μm to about 50 μm, or from about 30 μm to about 40 μm.
- The base of the microprojections of the present invention may have a length of about 25 μm, or about 30 μm, or about 35 μm, or about 40 μm, or about 45 μm, or about 50 μm, or about 55 μm, or about 60 μm, or about 65 μm, or about 70 μm, or about 75 μm, or about 80 μm, or about 85 μm, or about 90 μm or about 100 μm or about 200 μm, or about 300 μm, or about 350 μm, or about 400 μm, or about 450 μm, or about 500 μm, or about 550 μm, or about 600 μm, or about 650 μm, or about 700 μm, or about 750 μm, or about 800 μm, or about 850 μm, or about 900 μm or about 1000 μm or about 1500 μm or about 2000 μm. The base of the microprojections of the present invention may have a length of from about 30 μm to about 2 mm, or from about 30 μm to about 1.5 mm, or from about 30 μm to about 1 mm, or from about 30 μm to about 900 μm, or from about 30 μm to about 800 μm, or from about 30 μm to about 700 μm, or from about 30 μm to about 600 μm, or from about 30 μm to about 500 μm, or from about 30 μm to about 400 μm, or from about 30 μm to about 300 μm, or from about 30 μm to about 200 μm, or from about 30 μm to about 100 μm, or from about 30 μm to about 90 μm, or from about 30 μm to about 80 μm, or from about 30 μm to about 70 μm, or from about 30 μm to about 60 μm, or from about 30 μm to about 70 μm, or from about 30 μm to about 60 μm, or from about 30 μm to about 50 μm, or from about 50 μm to about 1.5 mm, or from about 50 μm to about 1 mm, or from about 50 μm to about 900 μm, or from about 50 μm to about 800 μm, or from about 50 μm to about 700 μm, or from about 50 μm to about 600 μm, or from about 50 μm to about 500 μm, or from about 50 μm to about 400 μm, or from about 50 μm to about 300 μm, or from about 50 μm to about 200 μm, or from about 50 μm to about 100 μm, or from about 50 μm to about 90 μm, or from about 50 μm to about 80 μm, or from about 50 μm to about 70 μm, or from about 50 μm to about 60 μm, or from about 80 μm to about 1.5 mm, or from about 80 μm to about 1 mm, or from about 80 μm to about 900 μm, or from about 80 μm to about 800 μm, or from about 80 μm to about 700 μm, or from about 80 μm to about 600 μm, or from about 80 μm to about 500 μm, or from about 80 μm to about 400 μm, or from about 80 μm to about 300 μm, or from about 80 μm to about 200 μm, or from about 80 μm to about 100 μm, or from about 80 μm to about 90 μm.
- The base of the microprojections of the present invention may have a thickness of about 5 μm, or about 10 μm, or about 15 μm, or about 20 μm, or about 25 μm, or about 30 μm, or about 35 μm, or about 40 μm, or about 45 μm, or about 50 μm, or about 55 μm, or about 60 μm, or about 65 μm, or about 70 μm, or about 75 μm, or about 80 μm, or about 85 μm, or about 90 μm or about 100 μm. The base of the microprojections of the present invention may have a thickness of from about 5 μm to about 100 μm, or from about 5 μm to about 95 μm, or from about 5 μm to about 90 μm, or from about 5 μm to about 85 μm, or from about 5 μm to about 80 μm, or from about 5 μm to about 75 μm, or from about 5 μm to about 70 μm, or from about 5 μm to about 65 μm, or from about 5 μm to about 60 μm, or from about 5 μm to about 55 μm, or from about 5 μm to about 50 μm, or from about 5 μm to about 45 μm, or from about 5 μm to about 40 μm, or from about 5 μm to about 35 μm, or from about 5 μm to about 30 μm, or from about 5 μm to about 25 μm, or from about 5 μm to about 20 μm, or from about 5 μm to about 15 μm, or from about 5 μm to about 10 μm, or from about 10 μm to about 100 μm, or from about 10 μm to about 95 μm, or from about 10 μm to about 90 μm, or from about 10 μm to about 85 μm, or from about 10 μm to about 80 μm, or from about 10 μm to about 75 μm, or from about 10 μm to about 70 μm, or from about 10 μm to about 65 μm, or from about 10 μm to about 60 μm, or from about 10 μm to about 55 μm, or from about 10 μm to about 50 μm, or from about 10 μm to about 45 μm, or from about 10 μm to about 40 μm, or from about 10 μm to about 35 μm, or from about 10 μm to about 30 μm, or from about 10 μm to about 25 μm, or from about 10 μm to about 20 μm, or from about 10 μm to about 15 μm, or from about 20 μm to about 100 μm, or from about 20 μm to about 95 μm, or from about 20 μm to about 90 μm, or from about 20 μm to about 85 μm, or from about 20 μm to about 80 μm, or from about 20 μm to about 75 μm, or from about 20 μm to about 70 μm, or from about 20 μm to about 65 μm, or from about 20 μm to about 60 μm, or from about 20 μm to about 55 μm, or from about 20 μm to about 50 μm, or from about 20 μm to about 45 μm, or from about 20 μm to about 40 μm, or from about 20 μm to about 35 μm, or from about 20 μm to about 30 μm, or from about 20 μm to about 25 μm, or from about 30 μm to about 100m, or from about 30 μm to about 95 μm, or from about 30 μm to about 90 μm, or from about 30 μm to about 85 μm, or from about 30 μm to about 80 μm, or from about 30 μm to about 75 μm, or from about 30 μm to about 70 μm, or from about 30 μm to about 65 μm, or from about 30 μm to about 60 μm, or from about 30 μm to about 55 μm, or from about 30 μm to about 50 μm, or from about 30 μm to about 45 μm, or from about 30 μm to about 40 μm, or from about 30 μm to about 35 μm.
- The base of the microprojections of the present invention have a cross sectional length:thickness aspect ratio of about 3:2, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, between 3:2 to 9:1, between 3:2 to 8:1, between 3:2 to 7:1, between 3:2 to 6:1; between 3:2 to 5:1, between 3:2 to 4:1, between 3:2 to 3:1, between 2:1 to 9:1, between 2:1 to 8:1, between 2:1 to 7:1, between 2:1 to 6:1; between 2:1 to 5:1, between 2:1 to 4:1, between 3:1 to 9:1, between 3:1 to 8:1, between 3:1 to 7:1, between 3:1 to 6:1; between 3:1 to 5:1, between 3:1 to 4:1, between 4:1 to 9:1, between 4:1 to 8:1, between 4:1 to 7:1, between 4:1 to 6:1; between 4:1 to 5:1, between 5:1 to 9:1, between 5:1 to 8:1, between 5:1 to 7:1, between 5:1 to 6:1, between 6:1 to 9:1, between 6:1 to 8:1, between 6:1 to 7:1, between 7:1 to 9:1, between 7:1 to 8:1, between 8:1 to 9:1. In this regard, a high aspect ratio can assist in having the projections penetrate the skin with minimal force. On a micro-scale, puncture is a function of crack formation and subsequent growth. The use of a high aspect ratio can assist in allowing cracks to form, thereby reducing the barrier to entry, whilst also maximising the surface area of the projections, which in turn maximises the amount of coating and hence payload that can be delivered. This means that significantly more surface area of the protrusion can enter the skin, without a large increase in energy.
- The height of the microprojections of the present invention depends upon the depth of penetration required. The height of the microprojections of the present invention may have a length of from about 30 μm to about 2 mm, or from about 30 μm to about 1.5 mm, or from about 30 μm to about 1 mm, or from about 30 μm to about 900m, or from about 30 μm to about 800 μm, or from about 30 μm to about 700 μm, or from about 30 μm to about 600 μm, or from about 30 μm to about 500 μm, or from about 30 μm to about 400 μm, or from about 30 μm to about 300 μm, or from about 30 μm to about 200 μm, or from about 30 μm to about 100 μm, or from about 30 μm to about 90 μm, or from about 30 μm to about 80 μm, or from about 30 μm to about 70 μm, or from about 30 μm to about 60 μm, or from about 30 μm to about 70 μm, or from about 30 μm to about 60 μm, or from about 30 μm to about 50 μm, or from about 50 μm to about 1.5 mm, or from about 50 μm to about 1 mm, or from about 50 μm to about 900 μm, or from about 50 μm to about 800 μm, or from about 50 μm to about 700 μm, or from about 50 μm to about 600 μm, or from about 50 μm to about 500 μm, or from about 50 μm to about 400 μm, or from about 50 μm to about 300 μm, or from about 50 μm to about 200 μm, or from about 50 μm to about 100 μm, or from about 50 μm to about 90 μm, or from about 50 μm to about 80 μm, or from about 50 μm to about 70 μm, or from about 50 μm to about 60 μm, or from about 80 μm to about 1.5 mm, or from about 80 μm to about 1 mm, or from about 80 μm to about 900 μm, or from about 80 μm to about 800 μm, or from about 80 μm to about 700 μm, or from about 80 μm to about 600 μm, or from about 80 μm to about 500 μm, or from about 80 μm to about 400 μm, or from about 80 μm to about 300 μm, or from about 80 μm to about 200 μm, or from about 80 μm to about 100 μm, or from about 80 μm to about 90 μm.
- The density of the microprojection on the microprojection arrays may be about 2000 microprojections/cm2, or about 2500 microprojections/cm2, or about 3000 microprojections/cm2, or about 3500 microprojections/cm2, or about 4000 microprojections/cm2, or about 4500 microprojections/cm2, or about 5000 microprojections/cm2, or about 5500 microprojections/cm2, or about 6000 microprojections/cm2, or about 6500 microprojections/cm2, or about 7000 microprojections/cm2, or about 7500 microprojections/cm2, or about 8000 microprojections/cm2, or about 8500 microprojections/cm2, or about 9000 microprojections/cm2, or about 9500 microprojections/cm2, or about 10000 microprojections/cm2, or about 11000 microprojections/cm2, or about 12000 microprojections/cm2, or about 13000 microprojections/cm2, or about 14000 microprojections/cm2, or about 15000 microprojections/cm2, or about 16000 microprojections/cm2, or about 17000 microprojections/cm2, or about 18000 microprojections/cm2, or about 19000 microprojections/cm2, or about 20000 microprojections/cm2. The density of the microprojection on the microprojection arrays may be from about 2000 to about 20000 microprojections/cm2, or from about 2000 to about 15000 microprojections/cm2, or from about to about 10000 microprojections/cm2, or from about 2000 to about 9000 microprojections/cm2, or from about 2000 to about 8000 microprojections/cm2, or from about 2000 to about 7500 microprojections/cm2, or from about 2000 to about 7000 microprojections/cm2, or from about 2000 to about 6000 microprojections/cm2, or from about 2000 to about 5000 microprojections/cm2, or from about 2000 to about 4000 microprojections/cm2, or from about 3000 to about 20000 microprojections/cm2, or from about 3000 to about 15000 microprojections/cm2, or from about to about 10000 microprojections/cm2, or from about 3000 to about 9000 microprojections/cm2, or from about 3000 to about 8000 microprojections/cm2, or from about 3000 to about 7500 microprojections/cm2, or from about 3000 to about 7000 microprojections/cm2, or from about 3000 to about 6000 microprojections/cm2, or from about 3000 to about 5000 microprojections/cm2, or from about 3000 to about 4000 microprojections/cm2, or from about 4000 to about 20000 microprojections/cm2, or from about 4000 to about 15000 microprojections/cm2, or from about to about 10000 microprojections/cm2, or from about 4000 to about 9000 microprojections/cm2, or from about 4000 to about 8000 microprojections/cm2, or from about 4000 to about 7500 microprojections/cm2, or from about 4000 to about 7000 microprojections/cm2, or from about 4000 to about 6000 microprojections/cm2, or from about 4000 to about 5000 microprojections/cm2, or from about 5000 to about 20000 microprojections/cm2, or from about 5000 to about 15000 microprojections/cm2, or from about to about 10000 microprojections/cm2, or from about 5000 to about 9000 microprojections/cm2, or from about 5000 to about 8000 microprojections/cm2, or from about 5000 to about 7500 microprojections/cm2, or from about 5000 to about 7000 microprojections/cm2, or from about 5000 to about 6000 microprojections/cm2.
- In one embodiment of the microprojections of the present invention the microprojections have a vertical shape that has an extruded base profile with a slight draught angle of approximately 0 to 20 degrees up to a transition point at which point the upper tip of the microprojection will slope towards the tip line at a greater angle.
- The microprojection arrays of the present invention are comprised of a plurality of microprojections. The microprojections may be arrayed in lines. The spacing between microprojections on a single line may be from about 10 μm to about 500 μm, or from about 10 μm to about 450 μm or from about 10 μm to about 400 μm of from about 10 μm to about 350 μm or from about 10 μm to about 300 μm or from about 10 μm to about 250 μm; or from about 10 μm to about 200 μm of from about 10 μm to about 150 μm or from about 10 μm to about 100 μm or from about 10 μm to about 50 μm; or from about 20 μm to about 500 μm, or from about 20 μm to about 450 μm or from about 20 μm to about 400 μm of from about 20 μm to about 350 μm or from about 20 μm to about 300 μm or from about 20 μm to about 250 μm; or from about 20 μm to about 200 μm of from about 20 μm to about 150 μm or from about 20 μm to about 100 μm or from about 20 μm to about 50 μm; or from about 30 μm to about 500 μm, or from about 30 μm to about 450 μm or from about 30 μm to about 400 μm of from about 30 μm to about 350 μm or from about 30 μm to about 300 μm or from about 30 μm to about 250 μm; or from about 30 μm to about 200 μm of from about 30 μm to about 150 μm or from about 30 μm to about 100 μm or from about 30 μm to about 50 μm; or from about 40 μm to about 500 μm, or from about 40 μm to about 450 μm or from about 40 μm to about 400 μm of from about 40 μm to about 350 μm or from about 40 μm to about 300 μm or from about 40 μm to about 250 μm; or from about 40 μm to about 200 μm of from about 40 μm to about 150 μm or from about 40 μm to about 100 μm or from about 40 μm to about 50 μm; or from about 50 μm to about 500 μm, or from about 50 μm to about 450 μm or from about 50 μm to about 400 μm of from about 50 μm to about 350 μm or from about 50 μm to about 300 μm or from about 50 μm to about 250 μm; or from about 50 μm to about 200 μm of from about 50 μm to about 150 μm or from about 50 μm to about 100 μm. The spacing between lines of microprojections 40 μm to about 500 μm, or from about 40 μm to about 450 μm or from about 40 μm to about 400 μm of from about 40 μm to about 350 μm or from about 40 μm to about 300 μm or from about 40 μm to about 250 μm; or from about 40 μm to about 200 μm of from about 40 μm to about 150 μm or from about 40 μm to about 100 μm; or from about 50 μm to about 500 μm, or from about 50 μm to about 450 μm or from about 50 μm to about 400 μm of from about 50 μm to about 350 μm or from about 50 μm to about 300 μm or from about 50 μm to about 250 μm; or from about 50 μm to about 200 μm of from about 50 μm to about 150 μm or from about 50 μm to about 100 μm; or from about 75 μm to about 500 μm, or from about 75 μm to about 450 μm or from about 75 μm to about 400 μm of from about 75 μm to about 350 μm or from about 75 μm to about 300 μm or from about 75 μm to about 250 μm; or from about 75 μm to about 200 μm of from about 75 μm to about 150 μm.
- In one embodiment of the present invention the microprojection has a tapering extended hexagonal shape with a rapidly tapering tip at the distal end. The microprojections have a spacing of 100 μm between adjacent lines and 80 μm between successive microprojections on the array (density about 8000/cm2). The tip of the protrusions tapers to a distal line of approximately 25 μm long and 1-2 μm wide.
- A gas jet coating process may be used to deposit liquid vaccine material in the coating solution onto the projection array. The process parameters (i.e. jet angle, jet velocity, solution viscosity, etc.) of the coating method can affect the degree to which the coating material is localized towards the tips of the projections, rather than the base. In addition to these process parameters, coating of the liquid material to the projections can be further enhanced by modifying the surface properties of the projections relative to the liquid coating material. The coating may be applied using a gas jet coating technique as described in WO/2009/079712. The microprojection arrays of the present invention may penetrate further into the skin than corresponding arrays with conical or cylindrical microprojections having the same length and delivered with the same energy. The microprojection arrays of the present invention may penetrate further by 10% or 20% or 30% or 40% or 50% or 60% or 70% or 80% or 90% or 100%. The microprojection arrays of the present invention may penetrate further by 10% to 200% or from 10% to 150% or from 10% to 100% or from 10% to 90% or from 10% to 80% or from 10% to 70% or from 10% to 60% or from 10% to 50% or from 10% to 40% or from 10% to 30% or from 10% to 20% or from 20% to 200% or from 20% to 150% or from 20% to 100% or from 20% to 90% or from 20% to 80% or from 20% to 70% or from 20% to 60% or from 20% to 50% or from 20% to 40% or from 20% to 30% or from 30% to 200% or from 30% to 150% or from 30% to 100% or from 30% to 90% or from 30% to 80% or from 30% to 70% or from 30% to 60% or from 30% to 50% or from 30% to 40% or from 40% to 200% or from 40% to 150% or from 40% to 100% or from 40% to 90% or from 40% to 80% or from 40% to 70% or from 40% to 60% or from 40% to 50% or from 50% to 200% or from 50% to 150% or from 50% to 100% or from 50% to 90% or from 50% to 80% or from 50% to 70% or from 50% to 60%.
- The microprojection arrays of the present invention may provide greater cell death in the cells surrounding the microprojections in the skin than corresponding arrays with conical or cylindrical microprojections having the same length and delivered with the same energy. The microprojection arrays of the present invention may provide cell death that is 10% or 20% or 30% or 40% or 50% or 60% or 70% or 80% or 90% or 100% greater. The microprojection arrays of the present invention may provide greater cell death by 10% to 200% or from 10% to 150% or from 10% to 100% or from 10% to 90% or from 10% to 80% or from 10% to 70% or from 10% to 60% or from 10% to 50% or from 10% to 40% or from 10% to 30% or from 10% to 20% or from 20% to 200% or from 20% to 150% or from 20% to 100% or from 20% to 90% or from 20% to 80% or from 20% to 70% or from 20% to 60% or from 20% to 50% or from 20% to 40% or from 20% to 30% or from 30% to 200% or from 30% to 150% or from 30% to 100% or from 30% to 90% or from 30% to 80% or from 30% to 70% or from 30% to 60% or from 30% to 50% or from 30% to 40% or from 40% to 200% or from 40% to 150% or from 40% to 100% or from 40% to 90% or from 40% to 80% or from 40% to 70% or from 40% to 60% or from 40% to 50% or from 50% to 200% or from 50% to 150% or from 50% to 100% or from 50% to 90% or from 50% to 80% or from 50% to 70% or from 50% to 60%.
- The microprojection arrays of the present invention may provide increased immunogenicity as compared to intramuscular administration of vaccine. The microprojection arrays of the present invention may provide increased immunogenicity as compared to corresponding arrays with conical or cylindrical microprojections having the same length and delivered with the same energy in delivering vaccines. The microprojection arrays of the present invention may provide an increased immunogenic response by 10% or 20% or 30% or 40% or 50% or 60% or 70% or 80% or 90% or 100%. The microprojection arrays of the present invention may provide an increased immunogenic response by 10% to 200% or from 10% to 150% or from 10% to 100% or from 10% to 90% or from 10% to 80% or from 10% to 70% or from 10% to 60% or from 10% to 50% or from 10% to 40% or from 10% to 30% or from 10% to 20% or from 20% to 200% or from 20% to 150% or from 20% to 100% or from 20% to 90% or from 20% to 80% or from 20% to 70% or from 20% to 60% or from 20% to 50% or from 20% to 40% or from 20% to 30% or from 30% to 200% or from 30% to 150% or from 30% to 100% or from 30% to 90% or from 30% to 80% or from 30% to 70% or from 30% to 60% or from 30% to 50% or from 30% to 40% or from 40% to 200% or from 40% to 150% or from 40% to 100% or from 40% to 90% or from 40% to 80% or from 40% to 70% or from 40% to 60% or from 40% to 50% or from 50% to 200% or from 50% to 150% or from 50% to 100% or from 50% to 90% or from 50% to 80% or from 50% to 70% or from 50% to 60%.
- The ability of the microprojection arrays of the present invention to provide a greater immunogenic response allows the microprojection arrays to deliver a lesser amount of vaccine to achieve the appropriate response as compared to intramuscular or intradermal administration by a needle. The ability of the microprojection arrays of the present invention to provide a greater immunogenic response allows the microprojection arrays to deliver a lesser amount of vaccine to achieve the appropriate response as compared to corresponding arrays with conical or cylindrical microprojection. Such “dose-sparing” benefit of the microprojection arrays permits a lesser amount of vaccine to be used in each dose to achieve the same immunogenic response. The amount of vaccine used with the microprojection arrays of the present invention may be 0.01%, 0.05%, 0.10%, 0.50%, 1%, 5% or 10% or 20% or 30% or 40% or 50% or 60% or 70% or 80% or 90% less than the amount of vaccine used in conventional vaccine administrations. The amount of vaccine used with the microprojection arrays of the present invention may be about 0.01% to 90% or from 0.01% to 80% or from 0.01% to 70% or from 0.01% to 60% or from 0.01% to 50% or from 0.01% to 40% or from 0.01% to 30% or from 0.01% to 20% or from 0.01% to 10% or from 0.01% to 1% or from 0.01% to 0.10% or from 0.05% to 90% or from 0.05% to 80% or from 0.05% to 70% or from 0.05% to 60% or from 0.05% to 50% or from 0.05% to 40% or from 0.05% to 30% or from 0.05% to 20% or from 0.05% to 10% or from 0.05% to 1% or from 0.05% to 0.10% or from 0.10% to 90% or from 0.10% to 80% or from 0.10% to 70% or from 0.10% to 60% or from 0.10% to 50% or from 0.10% to 40% or from 0.10% to 30% or from 0.10% to 20% or from 0.10% to 10% or from 0.10% to 1% or from 1% to 90% or from 1% to 80% or from 1% to 70% or from 1% to 60% or from 1% to 50% or from 1% to 40% or from 1% to 30% or from 1% to 20% or from 1% to 10% or from 5% to 90% or from 5% to 80% or from 5% to 70% or from 5% to 60% or from 5% to 50% or from 5% to 40% or from 5% to 30% or from 5% to 20% or from 5% to 10% or from 10% to 90% or from 10% to 80% or from 10% to 70% or from 10% to 60% or from 10% to 50% or from 10% to 40% or from 10% to 30% or from 10% to 20% or from 20% to 90% or from 20% to 80% or from 20% to 70% or from 20% to 60% or from 20% to 50% or from 20% to 40% or from 20% to 30% or from 30% to 90% or from 30% to 80% or from 30% to 70% or from 30% to 60% or from 30% to 50% or from 30% to 40% or from 40% to 90% or from 40% to 80% or from 40% to 70% or from 40% to 60% or from 40% to 50% or from 50% to 90% or from 50% to 80% or from 50% to 70% or from 50% to 60%.
- The amount of vaccine antigen given per dose may be from about 1 ng, 5 ng, 10 ng, 20 ng, 30 ng, 40 ng, 50 ng, 60 ng, 70 ng, 80 ng, 90 ng, 100 ng, 250 ng, 500 ng, 750 ng, 1 μg dose, 2 μg dose, 3 μg dose, 4 μg dose, 5 μg dose, 6μg dose, 7 μg dose, 8 μg dose, 9 μg dose, 10 μg dose, 15 μg dose, 20 μg dose, 25 μg dose, 30 μg, 40 μg dose, 50 μg dose, 60 μg dose, 70 μg dose, 80 μg dose may be sufficient to induce an immune response. The dose of vaccine antigen may be administered to the human within a range of doses including from about 1 ng to about 10 μg, about 1 ng to about 5 μg, about 1 ng to about 1 μg, about 1 ng to about 900 ng, about 1 ng to about 800 ng, about 1 ng to about 700 ng, about 1 ng to about 600 ng, about 1 ng to about 500 ng, about 1 ng to about 400 ng, about 1 ng to about 300 ng, about 1 ng to about 200 ng, about 1 ng to about 100 ng about 1 ng to about 75 ng, about 1 ng to about 50 ng, about 1 ng to about 25 ng, about 10 ng to about 10 μg, about 10 ng to about 5 μg, about 10 ng to about 1 μg, about 10 ng to about 900 ng, about 10 ng to about 800 ng, about 10 ng to about 700 ng, about 10 ng to about 600 ng, about 10 ng to about 500 ng, about 10 ng to about 400 ng, about 10 ng to about 300 ng, about 10 ng to about 200 ng, about 10 ng to about 100 ng, about 10 ng to about 75ng, about 10 ng to about 50 ng, about 10 ng to about 25ng, about 0.1 μg to about 500 μg, 1 μg to about 100 μg, 1 μg to about 50 μg, from about 1 μg to about 30 μg, from about 1 μg to about 25 μg, from about 1 μg to about 20 μg, from about 1 μg to about 15 μg, from about 1 μg to about 10 μg, from about 2 μg to about 50 μg, 2 μg to about 30 μg, from about 2 μg to about 20 μg, from about 2 μg to about 10 μg, from about 2 μg to about 8 μg, from about 3 μg to about 50 μg, 3 μg to about 30 μg, from about 3 μg to about 20 μg, from about 3 μg to about 10 μg, from about 3 μg to about 8 μg, from about 3 μg to about 5 μg, from about 4 μg to about 50 μg, 4 μg to about 30 μg, from about 4 μg to about 20 μg, from about 4 μg to about 10 μg, from about 4 μg to about 8 μg, from about 5 μg to about 50 μg, 5 μg to about 30 μg, from about 5 μg to about 20 μg, from about 5 μg to about 10 μg, from about 5 μg to about 9 μg, and from about 5 μg to about 8 μg.
- The microprojection array may be applied vertically, laterally or a combination thereof. A lateral application of the microprojection array will slide the microprojections along the surface of the skin to penetrate the skin in lanes.
- The applicators of the present invention utilize a ‘low-force, higher velocity’ applicator which may use a “flying” microprojection array in which the microprojection array is discharged from the device with sufficient force to propel the array through space and into the skin. Peak stresses are associated with the penetration of projections, without the follow-through, and the higher velocity achieves the change of behavior of the skin from elastic to plastic. The use of low force, high velocity approach to penetration of the skin by the microprojection array provides advantages such as: achieving equivalent penetration in the skin, but with about only 1/10th the Kinetic Energy; improved patient acceptability/tolerability of the penetration of the skin by the microprojection array and significantly less breakage of projections (up to about 1/10000 reduction of breakage) and patch base. The use of low force, high velocity application of the microprojection array to the skin also provides consistent penetration of the patch from site to site, because the mechanics of penetration are not heavily reliant on variations of the subcutaneous tissue (which does vary significantly within and individual and between people in populations). The direct correlation of kinetic energy with penetration may be utilized to design an applicator and microarray projections that provides maximal efficiency in delivering material to the patient while reducing discomfort to the patient.
- The speed of the microprojection array as it is projected into the skin depends at least in part upon the density of the projections in the microarray and the area of the array. The range of speeds for the microprojection array entering the skin may be from about 5 m/s to about 50 m/s or from about 5 m/s to about 40 m/s or from about 5 m/s to about 30 m/s or from about 5 m/s to about 25 m/s or from about 5 m/s to about 20 m/s or about 10 m/s to about 50 m/s or from about 10 m/s to about 40 m/s or from about 10 m/s to about 30 m/s or from about 10 m/s to about 25 m/s or from about 10 m/s to about 20 m/s or from about 20 m/s to about 50 m/s or from about 20 m/s to about 40 m/s or from about 20 m/s to about 30 m/s or from about 25 m/s to about 50 m/s or from about 25 m/s to about 40 m/s or from about 25 m/s to about 30 m/s. In preferred embodiments of the of the present invention the speed of the microprojection array is at least 15 m/s or at least 20 m/s or at least 25 m/s or at least 30 m/s.
- In one embodiment the microprojections have a tapering extended hexagonal shape with a rapidly tapering tip at the distal end. The protrusions have a spacing of 100 μm between adjacent lines and 80 μm between successive protrusions (density about 8000/cm2). The tip of the protrusions tapers to a distal line of approximately 25 μm long and 1-2 μm wide.
- An example of a
microprojection array 500 is shown inFIGS. 5A-5B . Themicroprojection array 500 comprises asubstrate 520 with a plurality ofmicroprojections 510 protruding from thesubstrate 520. Themicroprojection array 500 includesmicroprojections 510 arranged in a number of straight, spaced apart lines as shown inFIG. 5B . InFIG. 5A , the spacing of themicroprojections 510 between adjacent lines is indicated as S1 and the spacing betweensuccessive microprojections 510 in the same line is indicated as S2. - Further details of one of the
microprojections 510 of themicroprojection array 500 are shown inFIGS. 6A-6C . Themicroprojections 510 have a tapering hexagonal shape and comprise atip 611 and a base 612 wherein thebase 612 has two substantiallyparallel sides FIG. 6B by α1) up to atransition point 613 at which point the angle increases to from about 20 degrees to about 70 degrees (as indicated inFIG. 6B by α2). Although this example depicts a distinct increase in the angle at thetransition point 613, it should be noted that there may be a more gradual increase in the angle than depicted. Thetip 611 of eachmicroprojection 510 terminates in an elongate edge. Thetip 611 has a width Wtip and a length Ltip. Thebase 612 has a length Lbase, and is greater in length than thetip 611. Thebase 612 has a thickness Tbase. The cross sectional length:thickness aspect ratio of thebase 612 is defined as Lbase:Tbase, and is greater than 2:1 in this case. Each microprojection has an overall height H which depends upon the depth of penetration required. - In view of the above, it will be appreciated that the present invention relates to microarray projections which are designed to have a large surface area to frontal profile design while maintaining a high density configuration. The microprojection arrays of the present invention exploit the manner in which skin punctures. On a micro-scale, puncture is a function of crack formation in the skin and the subsequent growth of these cracks. While high density microneedles or microdevices perform this in a large number for every individual “needle”, it necessitates a very large number of crack initiations thereby absorbing substantial energy. The devices of the present invention use a lower density of protrusions compared to some high density arrays, which have a line of contact rather than a single contact point. Once the crack in the skin starts to form, the protrusion will easily enter the skin, allowing internal skin surface area contact with penetrating surface. This means that significantly more surface area for the protrusion to enter the skin. The microprojections of the present invention may be wider and thinner than current conically or cylindrically shaped microprojections. Thus, a single line of contact may cut into the skin rather than point punctures. The results are that a larger surface may be introduced into the skin rather than individual points penetrating the skin in which each point must be opened before vaccine may be delivered.
- The present invention relates to microprojection arrays where the microprojection design provides an alternative mode of skin puncture and vaccine delivery into the skin. The microprojections of the present invention are designed to have a large surface area to frontal profile design while maintaining a high density of microprojections on the array. The microprojection arrays of the present invention have a plurality of microprojections that are located upon a base. In one embodiment the microprojection have a shape that from a top down perspective is approximately an extended hexagon with two parallel sides being extended to give a rectangular profile with triangular ends. In an alternate embodiment the microprojections have a shape that from a top down perspective is approximately an extended octagon. This profile is similar to the hexagonally-shaped microprojection except that the ends of the microprojections are broadened. The microprojections may be aligned in parallel line with spacing between the edges of the microprojections. The microprojections may extend vertically to a length that will provide for drugs or vaccines to be delivered to the desired location within the skin.
- The present invention relates to microprojections having a tapering extended hexagonal or octagonal shape comprising a base and a tip wherein the tip has a width of from about 0.5 μm to about 2 μm and a length of about 10 μm to about 2 mm.
- The present invention relates to microprojection arrays comprising a plurality of microprojections wherein the microprojections have a tapering extended hexagonal shape or octagonal and comprise a base and a tip wherein the tip has a width of from about 0.5 μm to about 2 μm and a length of about 10 μm to about 2 mm.
- The present invention relates to microprojection arrays comprising a plurality of microprojections organized in lines on the array wherein the microprojections have a tapering extended hexagonal or octagonal shape and wherein the spacing of the microprojection between adjacent lines is 100 μm and the spacing between successive microprojections is 80 μm. The present invention relates to methods of administering a vaccine to a human comprising applying the microprojection arrays in which vaccine is coated onto the microprojections of the arrays of the present invention to a human's skin.
- The present invention relates to microprojection arrays comprising a substrate with a plurality of microprojections protruding from the substrate wherein the microprojections have a tapering hexagonal or octagonal shape and comprise a tip and a base wherein the base has two substantially parallel sides with a slight draught angle of approximately 1 to 20 degrees up to a transition point at which point the angle increases to from about 20 degrees to about 70 degrees.
- The present invention relates to microprojection arrays where the substrate is solid or non-porous or non-hollow. The present invention relates to microprojection arrays where the microprojection array includes a number of microprojections arranged in a line. The present invention relates to microprojection arrays where the line is a straight line or a curved line or a circular line extending circumferentially around an axis. The present invention relates to microprojection arrays where some of microprojections in a line have a common base. The present invention relates to microprojection arrays where the microprojection array includes a number of spaced apart lines. The present invention relates to microprojection arrays where the spacing of the microprojections between adjacent lines is less than 200 μm or less than 150 μm or about 100 μm. The present invention relates to microprojection arrays where the spacing between successive microprojections is less than 200 μm or less than 150 μm or less than 100 μm or about 80 μm.
- All microprojection arrays were coated in a solution of 1% methylcellulose and the required vaccine dose dissolved in injectable phosphate buffered saline solution (Chen, et al, J. Controlled Release (2009) 139, 212). Fluvax 2014® was used as the antigen. Delivered dose was measured using radioassay (Fernando, et al. PLos One (2010) 5, e10266). Specific pathogen-free female C57BL/6 mice from 6 to 8 weeks old were used in all examples. Groups of 5 mice were use in each Example. Application of all microprojection array patches were performed as described (Crichton et al., Biomaterials (2010) 31, 4562) at a velocity of 2.3 m/s. The surface area and volume of the projections entering the skin was calculated upon models using Solid Edge® software (Siemens PLM Software, Texas, US). Imaging of microprojection array puncturing and delivery into the skin was performed by coating the microprojections with Fluorospheres (Molecular Probes, OR, US) and applying the microprojection arrays to skin for histology or excised skin for CryoSEM and imaging as described (3). Trans-Epidermal water loss (TEWL) was measured using a Tewawater® TM300 (Courage & Khazajka Electronic GmbH, Cologne, Germany). Mice had TEWL measurement taken prior to microprojection array application, immediately post- microprojection array application and at 30, 60, 90 and 120 minutes and then every hour from 3-8 hours post application of the microprojection array. Two control mice that had not had microprojection arrays used on them were also measure during these timeframes to observe any environmental baseline changes. Visible staining of the tissue and quantification of live/dead cells was performed as described (Depelsebaire et al., J. Invest. Dermatol. (2014) 134, 2361). A total of n=4-5 fields of view were acquired per sample. Skin infiltrating cells were examined by flow cytometry. Excised ear tissue was diced and incubated in 1 mg/ml collagenase IV (Life Technologies, Carlsbad, CA) and 4U DNAse I (ThermoFisher Scientific, Pittsburgh, PA) for 30 minutes at 37° C. before inactivating with 200 uL of fetal bovine serum. Lysates were passed through a 70 μm strainer and cells pelleted by centrifugation with an additional 4U DNAse I treatment. Cells were incubated with purified anti-CD 16/32 (Clone 93, Biolegend, San Diego, CA) for 15 minutes at 4° C. before washing and staining with a cocktail of fluorescently—conjugated anti-mouse monoclonal antibodies for 30 minutes at 4° C. CD45.2 PercP Cy5.5 (clone 104), CD11c PECy7 (N418), Ly6C APC (HK1.4RUO) (all from Affymetrix, San Diego, CA) CD11b Brilliant Violet 605 (M1/70), F4/80 Brilliant Vioet 421 (BM8) (Biolegend, San Diego, CA) and Ly6G FITC (IA8), Siglec F PE (E50-2440) (Becton Dickenson, Franklin lakes, NJ). Data were acquired on a BD LSR II flow cytometer and analysed using Flowjo v9 (TreeStar, Ashland, OR). DRAQ 7 (Biostatus, Shepshed UK) was used to exclude dead cells before analysis. Doublets and debris were removed based on forward and side scatter properties before gating. Results were analysed using a one-way ANOVA with Tykey post-test in Graphpad Prism® Version 6.00. Ig titers were determined as described (Fernando, et al. J. Controlled Release (2102) 159, 215) except of K-Blue TMB substrate (ELISA systems) was added and the color reaction was developed for 5 minutes in the dark. The reaction was stopped by the addition of 50 ul of 1 M phosphoric acid and the plates were read spectrophotometrically at 450 nm.
- One embodiment of microprojections of the present invention (TP) and cylindrically/conically shaped microprojections (NP) were coated (Chen, et al, J. Controlled Release (2009) 139, 212) and the microprojection arrays were administered to mouse ear skin (Crichton, et al., Biomaterials (2010) 31, 4562).
FIG. 1 shows the microprojections before coating. The coating solution is localized around the tips of the microprojections. Post-skin application imaging demonstrated that the coating on the tips of the microprojections had been removed and that the microprojections had entered the skin as evidenced by the tide mark on the microprojections' surfaces. Both TP and NP microprojections show varied penetration over the array surface indicating the complexity of penetrating a topographically variable skin surface. The TP microprojection shows a deeper penetration indicating the full dermis had been penetrated whereas the NP microprojections appear to have penetrated the epidermis and upper dermis. There appears to be a greater overall coverage of delivery by TP when an overhead view is surveyed. - The mechanism of surface puncture was explored using CryoSEM which involved the freezing of skin with microprojections in place and then removing or fracturing the microprojection arrays and skin to show the state of the tissue in-situ. Clear puncture marks are created by both sets of microprojection arrays and the skin is entered without a large disruption of the adjacent tissue. When the microprojection arrays are withdrawn from the skin the holes in the skin quickly closed. In observing the TP microprojection array it was determined that the major axis of the hole created by the microprojections is 36 μm when the microprojection is in-situ. The hole shrinks by approximately 10 to 30% to 25 to 33 μm after withdrawal of the microprojection array. The minor axis shrinks to 5-10 μm after an initial width of 20 μm, a reduction of 50-75%. The data indicates much larger residual stress in opening a hole across the major axis as opposed to opening a hole along the major axis. This supports the concept that crack growth along the major axis of the microprojection will be the main driver of penetration which can serve to reduce residual stress concentrations along this axis. In contrast, cylindrical or circular holes made by microprojections where the major and minor axis are the same or similar will close from all direction with considerable residual stress from all side of the microprojection. This shape of microprojection provides no stress relief to assist the penetration process. Trans-Epidermal Water Loss was measured in skin penetrated by both TP and NP microprojections. The skin penetrated by NP microprojections healed more quickly that skin penetrated by TP microprojections consistent with view that large cracks are formed during TP microprojection penetration.
- Skin vaccine delivery depth was quantified by measuring the depth to which fluorescent dye coated onto the microprojections reached within the skin (Crichton, et al., Biomaterials (2010) 31, 4562). NP microprojections delivered to a depth of 39.9±16.4 μm (n=5 mouse ears; 337 total measurements) and TP microprojections delivered to a depth of 59.7±20.9 μm (n=4 mouse ears; 386 total measurements). The same amount of force was used to deliver the microprojections arrays to the skin. The TP microprojections were more successful in penetrating more deeply into the skin. A greater vaccine dose was delivered by the TP microprojections.
- To confirm increased penetration by TP projections a 3D model of both microprojections was constructed in Solid Edge®. The surface area and the volume of the TP and NP microprojection arrays were calculated and then scaled to account for all the microprojections on both arrays. The calculation indicated that for a single TP microprojection the volume entering the skin was 2-3 times that of an NP microprojection. Due to the large number of microprojections on the NP array, the overall volume of the microprojections in the skin summed over the entire array is similar between the NP and TP array for a given depth of penetration. The surface area of the two arrays is also similar. The increase penetration of the TP microprojections into the skin results from a greater ability to penetrate the skin rather than the disproportionate volume or surface area penetrating into the skin at comparable depths. The increase volume of the TP microprojections indicates easier entry into the skin which appears to be due to fewer penetrating microprojection into the skin and microprojections expanding punctures through the skin surface.
- Five ng of commercial influenza vaccine (Fluvax®) was administered to pathogen-free female C57BL/6 mice from 6 to 8 weeks old using intradermal injection, administration of NP microprojection array, administration of NP microprojection array, or intramuscular injection. The results are shown in
FIG. 3 . The immune response to the TP microprojection array which held 5 ng of antigen was equivalent to the NP microprojection array response to 50 ng of antigen which indicates a 10 fold increase in immunogenicity by altering the shape and dimensions of the microprojections. The increased immunogenicity exhibited by the TP microprojection array is similar to the inclusion of a chemical adjuvant using the NP microprojection array. The use of TP microprojection array in delivering 50 ng of vaccine proved to a potent immune enhancer more than doubling the IgG titer of the elicited by the NP at the same dose (as shown inFIGS. 3 and 4 ). - TP and NP microprojection arrays were applied to mouse ears and the skin stained for necrotic cell death and then imaged using confocal microscopy. An example of such an image is shown in
FIG. 2 . With respect to the NP microprojection arrays, cell death was observed within a radius of 20-30 μm with a greater number of dead cells on the edge of the array where bridged vaccine formulation restricted penetration but allowed significant force transmission into the skin. With respect to the TP microprojection arrays dead cells are observed primarily along the major axis of the microprojections. These extend approximately 5 -25 μm from the centerline of the microprojections indicating that this area is the area of highest stress upon insertion of the array. On the edges of the array where there is higher stress and where there is some bridging of coating between microprojections the fractures of adjacent microprojections joined to form lines of continuous surface fracture, bordered by necrotic cells. This supports the idea that stress distribution and the crack growth makes it easier for TP microprojections to enter the skin. Quantifying the level of cell death around microprojection arrays revealed that TP in the central array area had 54.7±18.6 dead cells surrounding it and NP in the central array area had 21.8±3.0 dead cells surrounding it. On the edge of the arrays, the TP field of view there was 17.6% greater cell death than in the NP array. In the central area of the arrays, the TP field of view there was 42.7% greater cell death than in the NP array. The level of cell death results in an increased level of inflammation throughout the tissue which may be a stimulating factor for an enhanced immune response. The number of neutrophils and macrophages after administration of the TP array increased as opposed to the NP array. There also was a trend toward an increase in monocytes and eosinophils as well. The inflamed microenvironment may give an improved environment for dendritic cells to uptake vaccine and subsequently enhance immunogenicity. - Ranges may be expressed herein as from about one particular value, and/or to about another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent about, it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.
- Throughout this specification and claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated integer or group of integers or steps but not the exclusion of any other integer or group of integers.
- Within this disclosure, any indication that a feature is optional is intended provide adequate support (e.g., under 35 U.S.C. 112 or Art. 83 and 84 of EPC) for claims that include closed or exclusive or negative language with reference to the optional feature. Exclusive language specifically excludes the particular recited feature from including any additional subject matter. For example, if it is indicated that A can be drug X, such language is intended to provide support for a claim that explicitly specifies that A consists of X alone, or that A does not include any other drugs besides X. “Negative” language explicitly excludes the optional feature itself from the scope of the claims. For example, if it is indicated that element A can include X, such language is intended to provide support for a claim that explicitly specifies that A does not include X. Non-limiting examples of exclusive or negative terms include “only,” “solely,” “consisting of,” “consisting essentially of,” “alone,” “without”, “in the absence of (e.g., other items of the same type, structure and/or function)” “excluding,” “not including”, “not”, “cannot,” or any combination and/or variation of such language.
- Similarly, referents such as “a,” “an,” “said,” or “the,” are intended to support both single and/or plural occurrences unless the context indicates otherwise. For example “a dog” is intended to include support for one dog, no more than one dog, at least one dog, a plurality of dogs, etc. Non-limiting examples of qualifying terms that indicate singularity include “a single”, “one,” “alone”, “only one,” “not more than one”, etc. Non-limiting examples of qualifying terms that indicate (potential or actual) plurality include “at least one,” “one or more,” “more than one,” “two or more,” “a multiplicity,” “a plurality,” “any combination of,” “any permutation of,” “any one or more of,” etc. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context.
- Where ranges are given herein, the endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or subrange within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
- All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
- While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that the various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
- Persons skilled in the art will appreciate that numerous variations and modifications will become apparent. All such variations and modifications which become apparent to persons skilled in the art, should be considered to fall within the spirit and scope that the invention broadly appearing before described.
Claims (11)
1-26. (canceled)
27. A microprojection array comprising a substrate with a plurality of microprojections protruding from the substrate wherein the microprojections have a tapering octagonal shape and comprise a tip and a base wherein the base has two substantially parallel sides with a slight draught angle of approximately 1 to 20 degrees up to a transition point at which point the angle increases to from about 20 degrees to about 70 degrees.
28. The microprojection array of claim 27 , wherein the substrate is at least one of:
a) solid;
b) non-porous; and
c) non-hollow.
29. The microprojection array of claim 27 , wherein the microprojection array includes a number of microprojections arranged in a line.
30. The microprojection array of claim 29 , wherein the line is at least one of:
a) a straight line;
b) a curved line; and,
c) a circular line extending circumferentially around an axis.
31. The microprojection array of claim 30 , wherein at least some of the microprojections in a line have a common base.
32. The microprojection array of claim 31 , wherein the microprojection array includes a number of spaced apart lines.
33. The microprojection array of claim 32 , wherein the spacing of the microprojections between adjacent lines is at least one of:
a) less than 200 μm;
b) less than 150 μm; and,
c) about 100 μm.
34. The microprojection array of claim 33 , wherein the spacing between successive microprojections is at least one of:
a) less than 200 μm;
b) less than 150 μm;
c) less than 100 μm; and,
d) about 80 μm.
35. The microprojection array of claim 27 , wherein the tip of each microprojection terminates in an elongate edge.
36. The microprojection array of claim 27 , wherein the tip has a width of from about 1 μm to about 2 μm and a length of about 20 μm to about 2 mm.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/303,333 US20230389945A1 (en) | 2015-09-18 | 2023-04-19 | Microprojection arrays with microprojections having large surface area profiles |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562220308P | 2015-09-18 | 2015-09-18 | |
PCT/AU2016/050867 WO2017045031A1 (en) | 2015-09-18 | 2016-09-16 | Microprojection arrays with microprojections having large surface area profiles |
US201815760869A | 2018-03-16 | 2018-03-16 | |
US17/393,096 US11653939B2 (en) | 2015-09-18 | 2021-08-03 | Microprojection arrays with microprojections having large surface area profiles |
US18/303,333 US20230389945A1 (en) | 2015-09-18 | 2023-04-19 | Microprojection arrays with microprojections having large surface area profiles |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/393,096 Continuation US11653939B2 (en) | 2015-09-18 | 2021-08-03 | Microprojection arrays with microprojections having large surface area profiles |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230389945A1 true US20230389945A1 (en) | 2023-12-07 |
Family
ID=58287979
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/760,869 Active 2038-02-19 US11103259B2 (en) | 2015-09-18 | 2016-09-16 | Microprojection arrays with microprojections having large surface area profiles |
US17/393,096 Active 2036-12-26 US11653939B2 (en) | 2015-09-18 | 2021-08-03 | Microprojection arrays with microprojections having large surface area profiles |
US18/303,333 Pending US20230389945A1 (en) | 2015-09-18 | 2023-04-19 | Microprojection arrays with microprojections having large surface area profiles |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/760,869 Active 2038-02-19 US11103259B2 (en) | 2015-09-18 | 2016-09-16 | Microprojection arrays with microprojections having large surface area profiles |
US17/393,096 Active 2036-12-26 US11653939B2 (en) | 2015-09-18 | 2021-08-03 | Microprojection arrays with microprojections having large surface area profiles |
Country Status (2)
Country | Link |
---|---|
US (3) | US11103259B2 (en) |
WO (1) | WO2017045031A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0402131D0 (en) | 2004-01-30 | 2004-03-03 | Isis Innovation | Delivery method |
EP2765927B1 (en) | 2011-10-12 | 2021-02-24 | Vaxxas Pty Limited | Delivery device |
EP3253440B1 (en) | 2015-02-02 | 2022-12-21 | Vaxxas Pty Limited | Microprojection array applicator |
US11103259B2 (en) * | 2015-09-18 | 2021-08-31 | Vaxxas Pty Limited | Microprojection arrays with microprojections having large surface area profiles |
DK3606760T3 (en) | 2017-03-31 | 2023-11-06 | Vaxxas Pty Ltd | ARRANGEMENT AND PROCEDURE FOR COATING SURFACES |
WO2018227246A1 (en) | 2017-06-13 | 2018-12-20 | Vaxxas Pty Limited | Quality control of substrate coatings |
EP3661587A4 (en) | 2017-08-04 | 2021-06-09 | Vaxxas Pty Limited | Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (map) |
Family Cites Families (231)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2213830A (en) | 1938-12-10 | 1940-09-03 | Anastasi John Joseph | Suturing and ligating instrument |
US2881500A (en) | 1958-07-03 | 1959-04-14 | Charles W Furness | Corneal clamp |
EP0139286B1 (en) | 1983-10-14 | 1991-08-21 | Sumitomo Pharmaceuticals Company, Limited | Prolonged sustained-release preparations |
US4702799A (en) | 1985-09-03 | 1987-10-27 | Nestec S.A. | Dryer and drying method |
US5017007A (en) | 1989-07-27 | 1991-05-21 | Milne Christopher G | Apparatus and microbase for surface-enhanced raman spectroscopy system and method for producing same |
WO1991006571A1 (en) | 1989-11-03 | 1991-05-16 | Immulogic Pharmaceutical Corporation | A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor |
US5201992A (en) | 1990-07-12 | 1993-04-13 | Bell Communications Research, Inc. | Method for making tapered microminiature silicon structures |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
US5657138A (en) | 1991-10-13 | 1997-08-12 | Lewis; Aaron | Generating defined structures on materials using combined optical technologies for transforming the processing beam |
WO1994024281A1 (en) | 1993-04-14 | 1994-10-27 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
AT397458B (en) | 1992-09-25 | 1994-04-25 | Avl Verbrennungskraft Messtech | SENSOR ARRANGEMENT |
US5461482A (en) | 1993-04-30 | 1995-10-24 | Hewlett-Packard Company | Electrical interconnect system for a printer |
US5449064A (en) | 1994-03-03 | 1995-09-12 | University Of Kansas | On-line interface and valve for capillary electophoresis system |
US5457041A (en) | 1994-03-25 | 1995-10-10 | Science Applications International Corporation | Needle array and method of introducing biological substances into living cells using the needle array |
FR2720003B1 (en) | 1994-05-23 | 1998-06-26 | Samsung Electro Mech | Device used to incise the skin for transcutaneous medication. |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5499474A (en) | 1994-11-28 | 1996-03-19 | Knooihuizen; Louis D. | Method and apparatus for liquid application |
JP3366146B2 (en) | 1995-03-06 | 2003-01-14 | セイコーエプソン株式会社 | Ink jet head |
AU5869796A (en) | 1995-05-22 | 1996-12-11 | Ned A. Godshall | Micromechanical patch for enhancing the delivery of compound s through the skin |
US6969635B2 (en) | 2000-12-07 | 2005-11-29 | Reflectivity, Inc. | Methods for depositing, releasing and packaging micro-electromechanical devices on wafer substrates |
DE69719761T2 (en) | 1996-06-18 | 2003-12-18 | Alza Corp | DEVICE FOR IMPROVING THE TRANSDERMAL ADMINISTRATION OF MEDICINAL PRODUCTS OR THE DETECTION OF BODY LIQUIDS |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
EP0957972B1 (en) | 1996-12-20 | 2003-03-19 | Alza Corporation | Device and method for enhancing transdermal agent flux |
AU5706598A (en) | 1996-12-24 | 1998-07-17 | Alza Corporation | Method and device for controlling mammalian reproductive cycle |
US5859937A (en) | 1997-04-04 | 1999-01-12 | Neomecs Incorporated | Minimally invasive sensor |
KR100219848B1 (en) | 1997-04-22 | 1999-09-01 | 이종수 | Method and apparatus for the structural analysis of a structure |
US5928207A (en) | 1997-06-30 | 1999-07-27 | The Regents Of The University Of California | Microneedle with isotropically etched tip, and method of fabricating such a device |
AUPP807899A0 (en) | 1999-01-08 | 1999-02-04 | University Of Queensland, The | Codon utilization |
WO1999002694A1 (en) | 1997-07-09 | 1999-01-21 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
US5943075A (en) | 1997-08-07 | 1999-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Universal fluid droplet ejector |
NL1008315C2 (en) | 1998-02-16 | 1999-08-25 | Stichting Fund Ond Material | Microdialysis probe integrated with Si chip. |
AU2872199A (en) | 1998-02-20 | 1999-09-06 | Rockefeller University, The | Apoptotic cell-mediated antigen presentation to dendritic cells |
US5870806A (en) | 1998-03-18 | 1999-02-16 | Black, Jr.; Robert P. | Bistable member for ejecting snap fastener and spring latch assemblies |
JP3372862B2 (en) | 1998-03-25 | 2003-02-04 | 株式会社日立製作所 | Biological fluid mass spectrometer |
US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
WO1999064580A1 (en) | 1998-06-10 | 1999-12-16 | Georgia Tech Research Corporation | Microneedle devices and methods of manufacture and use thereof |
GB9815819D0 (en) | 1998-07-22 | 1998-09-16 | Secr Defence | Transferring materials into cells and a microneedle array |
US6004815A (en) | 1998-08-13 | 1999-12-21 | The Regents Of The University Of California | Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells |
US7048723B1 (en) | 1998-09-18 | 2006-05-23 | The University Of Utah Research Foundation | Surface micromachined microneedles |
US6414501B2 (en) | 1998-10-01 | 2002-07-02 | Amst Co., Ltd. | Micro cantilever style contact pin structure for wafer probing |
US6610382B1 (en) | 1998-10-05 | 2003-08-26 | 3M Innovative Properties Company | Friction control article for wet and dry applications |
WO2000043552A2 (en) | 1999-01-25 | 2000-07-27 | Ut-Battelle, Llc | Multifunctional and multispectral biosensor devices and methods of use |
US20020004041A1 (en) | 1999-02-19 | 2002-01-10 | Albert Matthew L. | Methods for abrogating a cellular immune response |
US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
EP1187653B1 (en) | 1999-06-04 | 2010-03-31 | Georgia Tech Research Corporation | Devices for enhanced microneedle penetration of biological barriers |
US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
US6312612B1 (en) | 1999-06-09 | 2001-11-06 | The Procter & Gamble Company | Apparatus and method for manufacturing an intracutaneous microneedle array |
US6299621B1 (en) | 1999-06-18 | 2001-10-09 | Novare Surgical Systems, Inc. | Surgical clamp pads with elastomer impregnated mesh |
EP1065823A1 (en) | 1999-06-29 | 2001-01-03 | Siemens Aktiengesellschaft | Method for monitoring the bit transmission quality in a packet oriented transmission |
US6233797B1 (en) | 1999-07-13 | 2001-05-22 | Groz Beckert Kg | Felt needle |
DE19935165A1 (en) | 1999-07-28 | 2001-02-01 | Roche Diagnostics Gmbh | Method and arrangement for determining the concentration of glucose in a body fluid |
US6835184B1 (en) | 1999-09-24 | 2004-12-28 | Becton, Dickinson And Company | Method and device for abrading skin |
US6551849B1 (en) | 1999-11-02 | 2003-04-22 | Christopher J. Kenney | Method for fabricating arrays of micro-needles |
DE60024312T2 (en) | 1999-12-10 | 2006-08-17 | Alza Corp., Mountain View | Transdermal drug delivery of macromolecular agents and device therefor |
US6558361B1 (en) | 2000-03-09 | 2003-05-06 | Nanopass Ltd. | Systems and methods for the transport of fluids through a biological barrier and production techniques for such systems |
US6565532B1 (en) | 2000-07-12 | 2003-05-20 | The Procter & Gamble Company | Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup |
US6537242B1 (en) | 2000-06-06 | 2003-03-25 | Becton, Dickinson And Company | Method and apparatus for enhancing penetration of a member for the intradermal sampling or administration of a substance |
US6540675B2 (en) | 2000-06-27 | 2003-04-01 | Rosedale Medical, Inc. | Analyte monitor |
US6589202B1 (en) | 2000-06-29 | 2003-07-08 | Becton Dickinson And Company | Method and apparatus for transdermally sampling or administering a substance to a patient |
GB0017999D0 (en) | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
US6749575B2 (en) | 2001-08-20 | 2004-06-15 | Alza Corporation | Method for transdermal nucleic acid sampling |
US6533949B1 (en) | 2000-08-28 | 2003-03-18 | Nanopass Ltd. | Microneedle structure and production method therefor |
US7828827B2 (en) * | 2002-05-24 | 2010-11-09 | Corium International, Inc. | Method of exfoliation of skin using closely-packed microstructures |
IL155583A0 (en) | 2000-10-26 | 2003-11-23 | Alza Corp | Transdermal drug delivery devices having coated microprotrusions |
US9302903B2 (en) | 2000-12-14 | 2016-04-05 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
US6663820B2 (en) | 2001-03-14 | 2003-12-16 | The Procter & Gamble Company | Method of manufacturing microneedle structures using soft lithography and photolithography |
WO2002074173A1 (en) | 2001-03-16 | 2002-09-26 | Alza Corporation | Method and apparatus for coating skin piercing microprojections |
WO2002085447A2 (en) | 2001-04-20 | 2002-10-31 | Alza Corporation | Microprojection array having a beneficial agent containing coating |
US20020193729A1 (en) | 2001-04-20 | 2002-12-19 | Cormier Michel J.N. | Microprojection array immunization patch and method |
US6591124B2 (en) | 2001-05-11 | 2003-07-08 | The Procter & Gamble Company | Portable interstitial fluid monitoring system |
US7186235B2 (en) | 2001-06-08 | 2007-03-06 | Becton, Dickinson And Company | Device for manipulating a needle or abrader array and method of use |
US6767341B2 (en) | 2001-06-13 | 2004-07-27 | Abbott Laboratories | Microneedles for minimally invasive drug delivery |
US6557849B2 (en) | 2001-06-21 | 2003-05-06 | Da La Rue International | Sheet handling apparatus |
AT412060B (en) | 2001-07-06 | 2004-09-27 | Schaupp Lukas Dipl Ing Dr Tech | METHOD FOR MEASURING CONCENTRATIONS IN LIVING ORGANISMS BY MEANS OF MICRODIALYSIS AND AND DEVICE FOR IMPLEMENTING THIS METHOD |
US6881203B2 (en) | 2001-09-05 | 2005-04-19 | 3M Innovative Properties Company | Microneedle arrays and methods of manufacturing the same |
US20040087992A1 (en) | 2002-08-09 | 2004-05-06 | Vladimir Gartstein | Microstructures for delivering a composition cutaneously to skin using rotatable structures |
CA2500452A1 (en) | 2001-09-28 | 2003-04-03 | Biovalve Technologies, Inc. | Switchable microneedle arrays and systems and methods relating to same |
JP3835532B2 (en) | 2001-10-26 | 2006-10-18 | リコープリンティングシステムズ株式会社 | Inkjet printer |
AU2002367965A1 (en) | 2001-11-06 | 2003-12-31 | Dermal Systems International Inc. | High throughput methods and devices for assaying analytes in a fluid sample |
EP1485317A2 (en) | 2001-11-30 | 2004-12-15 | Alza Corporation | Methods and apparatuses for forming microprojection arrays |
EP1465535B1 (en) | 2001-12-20 | 2007-11-28 | ALZA Corporation | Skin-piercing microprojections having piercing depth control |
US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
DE10209763A1 (en) | 2002-03-05 | 2003-10-02 | Bosch Gmbh Robert | Device and method for anisotropic plasma etching of a substrate, in particular a silicon body |
US6704996B2 (en) | 2002-04-30 | 2004-03-16 | Lexmark International, Inc. | Method for making ink jet printheads |
AU2003222691A1 (en) | 2002-04-30 | 2003-11-17 | Morteza Shirkhanzadeh | Arrays of microneedles comprising porous calcium phosphate coating and bioactive agents |
JP3693115B2 (en) | 2002-05-13 | 2005-09-07 | セイコーエプソン株式会社 | Actuator device, liquid jet head, and inspection method thereof |
CN100591386C (en) | 2002-06-25 | 2010-02-24 | 权圣润 | Rapidly dissolving micro-perforator for drug delivery and other applications |
US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
US7052117B2 (en) | 2002-07-03 | 2006-05-30 | Dimatix, Inc. | Printhead having a thin pre-fired piezoelectric layer |
US7250037B2 (en) | 2002-07-22 | 2007-07-31 | Becton, Dickinson And Company | Patch-like infusion device |
US7081118B2 (en) | 2002-08-22 | 2006-07-25 | Helmut Weber | Medical tool |
AU2003275311A1 (en) | 2002-09-16 | 2004-04-30 | Sung-Yun Kwon | Solid micro-perforators and methods of use |
US7045069B2 (en) | 2002-11-14 | 2006-05-16 | Gennady Ozeryansky | Microfabrication method based on metal matrix composite technology |
US20040161470A1 (en) | 2002-11-22 | 2004-08-19 | Alexander Andrianov | Preparation of polyphosphazene microspheres |
EP1605835A4 (en) | 2003-03-06 | 2007-12-05 | Applied Med Resources | Spring clip and method for assembling same |
DE10328730B4 (en) | 2003-06-25 | 2006-08-17 | Micronas Gmbh | Method for producing a microarray and device for providing a carrier for a microarray with coating materials |
US20050089554A1 (en) | 2003-10-24 | 2005-04-28 | Cormier Michel J. | Apparatus and method for enhancing transdermal drug delivery |
WO2005044139A2 (en) | 2003-10-28 | 2005-05-19 | Alza Corporation | Method and apparatus for reducing the incidence of tobacco use |
ATE539687T1 (en) | 2003-10-31 | 2012-01-15 | Alza Corp | SELF-ACTUATED APPLICATOR FOR A MICROPROJECTION ARRANGEMENT |
WO2005044364A1 (en) * | 2003-11-10 | 2005-05-19 | Agency For Science, Technology And Research | Microneedles and microneedle fabrication |
MXPA06005509A (en) | 2003-11-13 | 2007-05-23 | Johnson & Johnson | System and method for transdermal delivery. |
US7753888B2 (en) | 2003-11-21 | 2010-07-13 | The Regents Of The University Of California | Method and/or apparatus for puncturing a surface for extraction, in situ analysis, and/or substance delivery using microneedles |
IL160033A0 (en) | 2004-01-25 | 2004-06-20 | Transpharma Medical Ltd | Transdermal delivery system for polynucleotides |
WO2005072360A2 (en) | 2004-01-27 | 2005-08-11 | Buyerleverage | System and method for granting deposit-contingent e-mailing rights |
GB0402131D0 (en) | 2004-01-30 | 2004-03-03 | Isis Innovation | Delivery method |
US20080312669A1 (en) | 2004-03-31 | 2008-12-18 | Vries Luc De | Surgical instrument and method |
US7591806B2 (en) | 2004-05-18 | 2009-09-22 | Bai Xu | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
ES2650188T3 (en) | 2004-06-10 | 2018-01-17 | 3M Innovative Properties Company | Device and patch application kit |
JP2006029881A (en) | 2004-07-14 | 2006-02-02 | Hitachi High-Technologies Corp | Inspection method of pattern defect and inspection device thereof |
TWI246929B (en) | 2004-07-16 | 2006-01-11 | Ind Tech Res Inst | Microneedle array device and its fabrication method |
US7316665B2 (en) | 2004-08-25 | 2008-01-08 | Becton, Dickinson And Company | Method and device for the delivery of a substance including a covering |
US7524430B2 (en) | 2004-09-10 | 2009-04-28 | Lexmark International, Inc. | Fluid ejection device structures and methods therefor |
US20080009811A1 (en) | 2004-11-18 | 2008-01-10 | 3M Innovative Properties Company | Non-Skin-Contacting Microneedle Array Applicator |
EP1827564B1 (en) | 2004-11-18 | 2015-07-29 | 3M Innovative Properties Company | Masking method for coating a microneedle array |
WO2006055795A1 (en) | 2004-11-18 | 2006-05-26 | 3M Innovative Properties Company | Low-profile microneedle array applicator |
WO2006101459A1 (en) | 2005-03-23 | 2006-09-28 | Agency For Science, Technology And Research | Microneedles |
WO2006108185A1 (en) | 2005-04-07 | 2006-10-12 | 3M Innovative Properties Company | System and method for tool feedback sensing |
US20060253079A1 (en) | 2005-04-25 | 2006-11-09 | Mcdonough Justin | Stratum corneum piercing device |
US20070270738A1 (en) | 2005-04-25 | 2007-11-22 | Wu Jeffrey M | Method of treating ACNE with stratum corneum piercing patch |
WO2006121510A2 (en) | 2005-05-09 | 2006-11-16 | Theranos, Inc. | Point-of-care fluidic systems and uses thereof |
US8043250B2 (en) * | 2005-05-18 | 2011-10-25 | Nanomed Devices, Inc. | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
CA2612005C (en) | 2005-06-17 | 2013-10-29 | Georgia Tech Research Corporation | Coated microstructures and method of manufacture thereof |
CA2612307A1 (en) | 2005-06-21 | 2007-01-04 | Alza Corporation | Method and device for coating a continuous strip of microprojection members |
CA2613111C (en) | 2005-06-27 | 2015-05-26 | 3M Innovative Properties Company | Microneedle array applicator device and method of array application |
AU2006261899B2 (en) | 2005-06-27 | 2012-05-10 | Kindeva Drug Delivery L.P. | Microneedle cartridge assembly and method of applying |
US20070027474A1 (en) | 2005-07-15 | 2007-02-01 | Jeffrey Lasner | Pressure limiting forceps |
JP2009502261A (en) | 2005-07-25 | 2009-01-29 | ナノテクノロジー ビクトリア ピーティーワイ リミテッド | Microarray device |
CA2629393C (en) | 2005-09-06 | 2014-06-10 | Theraject, Inc. | Solid solution perforator containing drug particle and/or drug-adsorbed particles |
US20070078376A1 (en) | 2005-09-30 | 2007-04-05 | Smith Gregory A | Functionalized microneedles transdermal drug delivery systems, devices, and methods |
WO2007054090A1 (en) | 2005-11-09 | 2007-05-18 | Pharmexa A/S | Therapeutic vaccines targeting hmgb1 |
EP1948139A4 (en) | 2005-11-18 | 2012-04-04 | 3M Innovative Properties Co | Coatable compositions, coatings derived therefrom and microarrays having such coatings |
US8524303B2 (en) | 2005-11-23 | 2013-09-03 | The Coca-Cola Company | High-potency sweetener composition with phytosterol and compositions sweetened therewith |
US8554317B2 (en) | 2005-11-30 | 2013-10-08 | 3M Innovative Properties Company | Microneedle arrays and methods of use thereof |
US8308960B2 (en) | 2005-12-14 | 2012-11-13 | Silex Microsystems Ab | Methods for making micro needles and applications thereof |
US7658728B2 (en) | 2006-01-10 | 2010-02-09 | Yuzhakov Vadim V | Microneedle array, patch, and applicator for transdermal drug delivery |
GB0600795D0 (en) | 2006-01-16 | 2006-02-22 | Functional Microstructures Ltd | Method of making microneedles |
JP5028872B2 (en) | 2006-03-02 | 2012-09-19 | 凸版印刷株式会社 | Manufacturing method of needle-shaped body |
US20070224252A1 (en) | 2006-03-27 | 2007-09-27 | Trautman Joseph C | Microprojections with capillary control features and method |
US9119945B2 (en) | 2006-04-20 | 2015-09-01 | 3M Innovative Properties Company | Device for applying a microneedle array |
EP2010269A4 (en) | 2006-04-25 | 2009-06-03 | Alza Corp | Microprojection array application with sculptured microprojections for high drug loading |
WO2007127815A2 (en) | 2006-04-25 | 2007-11-08 | Alza Corporation | Microprojection array application with multilayered microprojection member for high drug loading |
WO2007127976A2 (en) | 2006-05-01 | 2007-11-08 | Georgia Tech Research Corporation | Particle based molding |
US7425465B2 (en) | 2006-05-15 | 2008-09-16 | Fujifilm Diamatix, Inc. | Method of fabricating a multi-post structures on a substrate |
KR100793615B1 (en) | 2006-07-21 | 2008-01-10 | 연세대학교 산학협력단 | A biodegradable solid type microneedle and methods for preparing it |
WO2008011625A2 (en) | 2006-07-21 | 2008-01-24 | Georgia Tech Researh Corporation | Microneedle devices and methods of drug delivery or fluid withdrawal |
EP2062612A4 (en) * | 2006-08-18 | 2010-01-06 | Toppan Printing Co Ltd | Microneedle and microneedle patch |
WO2008053481A1 (en) | 2006-11-01 | 2008-05-08 | Svip 6 Llc | Microneedle arrays |
JP2008114561A (en) | 2006-11-08 | 2008-05-22 | Ricoh Co Ltd | Liquid discharge head, liquid discharge device, and image forming device |
KR20080051342A (en) | 2006-12-05 | 2008-06-11 | 연세대학교 산학협력단 | A microneedle device and methods for applicating it |
WO2008083209A2 (en) | 2006-12-29 | 2008-07-10 | Amir Genosar | Hypodermic drug delivery reservoir and apparatus |
DE102007002832A1 (en) | 2007-01-19 | 2008-07-24 | Robert Bosch Gmbh | Method for manufacturing device with arrangement of micro-needles, involves preparing silicon semiconductor substrate, whose surface is applied and structured with masking layer |
EP2121111B1 (en) | 2007-01-22 | 2018-03-14 | Corium International, Inc. | Applicators for microneedle arrays |
US20090017210A1 (en) | 2007-07-09 | 2009-01-15 | Andrianov Alexander K | Methods and systems for coating a microneedle with a dosage of a biologically active compound |
US20090041810A1 (en) | 2007-07-09 | 2009-02-12 | Andrianov Alexander K | Immunostimulating polyphosphazene compounds for intradermal immunization |
WO2009040548A1 (en) | 2007-09-28 | 2009-04-02 | The Queen's University Of Belfast | Delivery device and method |
WO2009051147A1 (en) | 2007-10-18 | 2009-04-23 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle device |
US8491534B2 (en) | 2007-11-21 | 2013-07-23 | Bioserentach Co., Ltd. | Preparation for body surface application and preparation for body surface application-holding sheet |
GB0724402D0 (en) | 2007-12-14 | 2008-01-30 | Univ Leiden | Microneedle injecting apparatus and method |
GB0725018D0 (en) | 2007-12-21 | 2008-01-30 | Univ Cardiff | Monitoring system for microneedle delivery |
EP2231257A4 (en) | 2007-12-24 | 2013-11-06 | Univ Queensland | Coating method |
CN101214395A (en) | 2008-01-02 | 2008-07-09 | 西南交通大学 | Inorganic material surface biological method |
CA2749347C (en) | 2008-02-07 | 2018-03-27 | The University Of Queensland | Patch production |
CA2760680A1 (en) | 2008-05-23 | 2009-11-26 | The University Of Queensland | Analyte detection by microneedle patch with analyte selective reagents |
CN101297989B (en) | 2008-06-19 | 2010-06-23 | 上海交通大学 | Batch preparation of hollow micro-needle based on molding |
KR101578420B1 (en) | 2008-06-30 | 2015-12-17 | 히사미쓰 세이야꾸 가부시키가이샤 | Microneedle device, and method for enhancing the efficacy of influenza vaccine by using microneedle device |
JP2010071845A (en) | 2008-09-19 | 2010-04-02 | Toppan Printing Co Ltd | Inspection device |
US20110288484A1 (en) | 2008-10-16 | 2011-11-24 | The Univeristy Of Queensland | Method and associated apparatus for coating projections on a patch assembly |
US20110021996A1 (en) | 2008-12-18 | 2011-01-27 | Miti Systems Inc. | Structure of micro-needle with side channel and manufacturing method thereof |
CA2760573A1 (en) | 2008-12-22 | 2010-07-01 | The University Of Queensland | Patch production |
WO2012018486A2 (en) | 2010-07-26 | 2012-02-09 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
US20120078293A1 (en) | 2009-03-27 | 2012-03-29 | Technion Research & Development Foundation Ltd. | Applicators for patches and adhesives |
EP2429627B1 (en) | 2009-04-24 | 2017-06-14 | Corium International, Inc. | Methods for manufacturing microprojection arrays |
ES2826882T3 (en) | 2009-07-23 | 2021-05-19 | Hisamitsu Pharmaceutical Co | Microneedle array |
CN102740800A (en) | 2010-01-29 | 2012-10-17 | 爱尔康医药有限公司 | Biodegradable protrusions on inflatable device |
US8911422B2 (en) | 2010-02-24 | 2014-12-16 | Hisamitsu Pharmaceutical Co., Inc. | Micro-needle device |
US20110306853A1 (en) | 2010-03-19 | 2011-12-15 | Michael Darryl Black | Body fluid sampling/fluid delivery device |
AU2011311255B2 (en) | 2010-04-28 | 2015-10-08 | Sorrento Therapeutics, Inc. | Method for increasing permeability of an epithelial barrier |
WO2011140240A2 (en) | 2010-05-04 | 2011-11-10 | Corium International, Inc. | Applicators for microneedles |
EP2576536B1 (en) | 2010-06-01 | 2016-09-14 | The University of Queensland | Haematopoietic-prostaglandin d2 synthase inhibitors |
US9943673B2 (en) | 2010-07-14 | 2018-04-17 | Vaxxas Pty Limited | Patch applying apparatus |
MX2013004660A (en) | 2010-10-25 | 2013-10-28 | Teijin Ltd | Microneedle. |
US9017289B2 (en) | 2010-11-03 | 2015-04-28 | Covidien Lp | Transdermal fluid delivery device |
US8540672B2 (en) | 2010-12-22 | 2013-09-24 | Valeritas, Inc. | Microneedle patch applicator |
WO2012103257A2 (en) | 2011-01-25 | 2012-08-02 | The Regents Of The University Of California | Transcutaneous multimodal delivery systems |
US8997572B2 (en) | 2011-02-11 | 2015-04-07 | Washington University | Multi-focus optical-resolution photoacoustic microscopy with ultrasonic array detection |
CA2829352A1 (en) | 2011-03-07 | 2012-09-13 | 3M Innovative Properties Company | Microneedle devices and methods |
EP2497463A1 (en) | 2011-03-09 | 2012-09-12 | Rogier Biemans | Method of protecting biologically active substances against denaturation |
US8512286B2 (en) | 2011-04-18 | 2013-08-20 | Medtronic, Inc. | Detecting a full reservoir of an implantable infusion device |
JP2014516644A (en) | 2011-04-29 | 2014-07-17 | セブンス センス バイオシステムズ,インコーポレーテッド | Devices and methods for collection and / or manipulation of blood spots or other body fluids |
KR102013466B1 (en) | 2011-04-29 | 2019-08-22 | 세븐쓰 센스 바이오시스템즈, 인크. | Delivering and/or receiving fluids |
JP2013043034A (en) | 2011-08-26 | 2013-03-04 | Dainippon Printing Co Ltd | Method for manufacturing microneedle device |
JP5682513B2 (en) | 2011-09-06 | 2015-03-11 | 株式会社村田製作所 | Fluid control device |
JP6265740B2 (en) | 2011-10-06 | 2018-01-24 | 久光製薬株式会社 | applicator |
EP2765927B1 (en) * | 2011-10-12 | 2021-02-24 | Vaxxas Pty Limited | Delivery device |
CA2851620A1 (en) | 2011-10-12 | 2013-04-18 | 3M Innovative Properties Company | Integrated microneedle array delivery system |
US8469490B2 (en) | 2011-10-26 | 2013-06-25 | Eastman Kodak Company | Ink tank configuration for inkjet printer |
US20150080844A1 (en) | 2012-04-02 | 2015-03-19 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure by intradermal infusion |
ES2761255T3 (en) | 2012-04-05 | 2020-05-19 | Hisamitsu Pharmaceutical Co | Lancing device |
WO2014058746A1 (en) | 2012-10-10 | 2014-04-17 | 3M Innovative Properties Company | Force-controlled applicator for applying a microneedle device to skin |
EP2974768A4 (en) | 2013-03-12 | 2017-05-17 | Takeda Pharmaceutical Company Limited | Micro-needle patch |
US10624865B2 (en) | 2013-03-14 | 2020-04-21 | Pathak Holdings Llc | Methods, compositions, and devices for drug/live cell microarrays |
WO2014150285A2 (en) | 2013-03-15 | 2014-09-25 | Corium International, Inc. | Multiple impact microprojection applicators and methods of use |
EP2968116A1 (en) * | 2013-03-15 | 2016-01-20 | Corium International, Inc. | Microarray with polymer-free microstructures, methods of making, and methods of use |
CA2904335C (en) | 2013-03-15 | 2022-03-29 | Corium International, Inc. | Microstructure array for delivery of active agents |
RU2720808C2 (en) | 2013-09-03 | 2020-05-13 | Джорджия Тек Рисёч Корпорейшн | Thermostable vaccines and microneedles |
AT514967B1 (en) | 2013-10-25 | 2015-08-15 | Zizala Lichtsysteme Gmbh | Microprojection light module for a motor vehicle headlight |
US20160310412A1 (en) | 2013-12-16 | 2016-10-27 | Takeda Pharmaceutical Company Limited | Microneedle |
WO2015152360A1 (en) * | 2014-04-04 | 2015-10-08 | 富士フイルム株式会社 | Microneedle array preparation comprising inactivated whole virus vaccine and method for administering same |
WO2015168738A1 (en) * | 2014-05-06 | 2015-11-12 | Mupharma Pty Ltd | Non-invasive agent applicator |
JP6565906B2 (en) * | 2014-05-20 | 2019-08-28 | 凸版印刷株式会社 | Needle-like body manufacturing method and needle-like body |
EP3216482B1 (en) * | 2014-11-06 | 2019-03-20 | Toppan Printing Co., Ltd. | Transdermal delivery device and method for manufacturing transdermal delivery device |
EP3253440B1 (en) | 2015-02-02 | 2022-12-21 | Vaxxas Pty Limited | Microprojection array applicator |
JP6268114B2 (en) | 2015-03-09 | 2018-01-24 | 富士フイルム株式会社 | Microneedle inspection method |
JP6487728B2 (en) | 2015-03-10 | 2019-03-20 | 富士フイルム株式会社 | Measuring system, measuring method and measuring program |
JP6411395B2 (en) * | 2015-03-10 | 2018-10-24 | 富士フイルム株式会社 | Method for producing transdermal absorption sheet |
US10441768B2 (en) * | 2015-03-18 | 2019-10-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bioactive components conjugated to substrates of microneedle arrays |
CN107405477B (en) * | 2015-03-18 | 2020-06-16 | 凸版印刷株式会社 | Drug administration device and method for manufacturing drug administration device |
JPWO2017047437A1 (en) * | 2015-09-17 | 2018-08-02 | Aof株式会社 | Micro needle |
US11103259B2 (en) * | 2015-09-18 | 2021-08-31 | Vaxxas Pty Limited | Microprojection arrays with microprojections having large surface area profiles |
CA2999538A1 (en) | 2015-09-28 | 2017-04-06 | Vaxxas Pty Limited | Microprojection arrays with enhanced skin penetrating properties and methods thereof |
CA3007753C (en) * | 2015-12-28 | 2021-07-06 | Endoderma Co., Ltd. | Microstructure for transdermal absorption and method for manufacturing same |
CA3010974A1 (en) | 2016-01-11 | 2017-07-20 | Verndari, Inc. | Microneedle compositions and methods of using same |
JP2017176460A (en) | 2016-03-30 | 2017-10-05 | 富士フイルム株式会社 | Method of manufacturing sheet with needle-like protrusion part |
JP6736337B2 (en) | 2016-04-15 | 2020-08-05 | 富士フイルム株式会社 | Micro needle array |
US11241563B2 (en) | 2016-12-22 | 2022-02-08 | Johnson & Johnson Consumer Inc. | Microneedle arrays and methods for making and using |
DK3606760T3 (en) | 2017-03-31 | 2023-11-06 | Vaxxas Pty Ltd | ARRANGEMENT AND PROCEDURE FOR COATING SURFACES |
WO2018227246A1 (en) | 2017-06-13 | 2018-12-20 | Vaxxas Pty Limited | Quality control of substrate coatings |
EP3661587A4 (en) | 2017-08-04 | 2021-06-09 | Vaxxas Pty Limited | Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (map) |
AU2018315629A1 (en) | 2017-08-10 | 2020-02-27 | Vaxxas Pty Limited | Differential coating of microprojections and microneedles on arrays |
US10422881B1 (en) | 2018-12-07 | 2019-09-24 | Didi Research America, Llc | Mirror assembly for light steering |
CN113993560A (en) | 2019-02-01 | 2022-01-28 | 麻省理工学院 | System and method for liquid injection |
-
2016
- 2016-09-16 US US15/760,869 patent/US11103259B2/en active Active
- 2016-09-16 WO PCT/AU2016/050867 patent/WO2017045031A1/en active Application Filing
-
2021
- 2021-08-03 US US17/393,096 patent/US11653939B2/en active Active
-
2023
- 2023-04-19 US US18/303,333 patent/US20230389945A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11103259B2 (en) | 2021-08-31 |
US11653939B2 (en) | 2023-05-23 |
WO2017045031A1 (en) | 2017-03-23 |
US20220015782A1 (en) | 2022-01-20 |
US20180263641A1 (en) | 2018-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11653939B2 (en) | Microprojection arrays with microprojections having large surface area profiles | |
Chen et al. | Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin | |
Kim et al. | Microneedles for drug and vaccine delivery | |
KR101578420B1 (en) | Microneedle device, and method for enhancing the efficacy of influenza vaccine by using microneedle device | |
EP1439870B1 (en) | Device for the delivery of a substance | |
Crichton et al. | The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine | |
US9782574B2 (en) | Force-controlled applicator for applying a microneedle device to skin | |
RU2494769C2 (en) | Package of hollow microneedles and method of using it | |
EP3881781B1 (en) | Delivery device | |
JP2020032211A (en) | Hollow microneedle with bevel opening | |
US20050271684A1 (en) | Apparatus and method for transdermal delivery of multiple vaccines | |
JP2019103822A (en) | Article comprising microneedle | |
Bernadete Riemma Pierre et al. | Microneedle-based drug delivery systems for transdermal route | |
US20050153873A1 (en) | Frequency assisted transdermal agent delivery method and system | |
CN107206221B (en) | Microneedle arrays and methods of use | |
US20050112135A1 (en) | Ultrasound assisted transdermal vaccine delivery method and system | |
US20090012494A1 (en) | Intradermal delivery of biological agents | |
JP2016511014A (en) | Microarrays for delivering therapeutic agents and methods of use | |
JP2016511014A5 (en) | ||
CN105246541A (en) | Microneedle injection apparatus comprising a dual cover | |
JP2004531578A (en) | Intradermal delivery of vaccines and gene therapeutics by microcannula | |
BR112020007566A2 (en) | applicator to apply a microneedle matrix to the skin | |
Stoeber et al. | Microneedling in Clinical Practice | |
Peterson | Microstructured transdermal systems for intradermal vaccine and drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |